Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,33170484,time to maximum pimasertib concentration,"The median time to maximum pimasertib concentration was 1.5 h across dosing schedules, and the apparent terminal half-life was 5 h across qd dosing schedules.",Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33170484/),h,1.5,271,DB02701,Nicotinamide
,33170484,apparent terminal half-life,"The median time to maximum pimasertib concentration was 1.5 h across dosing schedules, and the apparent terminal half-life was 5 h across qd dosing schedules.",Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33170484/),h,5,272,DB02701,Nicotinamide
,21487100,steady-state plasma exposure,A dose of 60 mg/kg in mice produced a human equivalent sorafenib steady-state plasma exposure of 10 μM.,Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21487100/),μM,10,297,DB02701,Nicotinamide
,30283402,EC50,ZB-16 exhibits nanomolar activity (EC50 = 7.3-9.7 nM) on target receptor GPR119 in vitro associated with hypoglycemic activity in vivo.,Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30283402/),nM,7.3-9.7,1545,DB02701,Nicotinamide
more,30283402,half-life,"ZB-16 demonstrated relatively low plasma exposition, high distribution volume, mild clearance and a prolonged half-life (more than 12 h).",Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30283402/),h,12,1546,DB02701,Nicotinamide
,23217964,half-life,"In human subjects, AZD5213 was safe and well tolerated following repeated doses (1-14 mg/d) and demonstrated a short (∼5 h) half-life.","AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23217964/),h,∼5,3368,DB02701,Nicotinamide
,23217964,"K i,pl","The plasma concentrations and the affinity constant (K i,pl 1.14 nmol/l, corresponding to the plasma concentration required to occupy 50% of available receptors) were used to estimate the H3RO time-course.","AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23217964/),[nM] / [l],1.14,3369,DB02701,Nicotinamide
,22549288,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) of sorafenib in combination with ILI-M was 400 mg.,A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22549288/),mg,400,3531,DB02701,Nicotinamide
,18971935,objective response rate,"The objective response rate was 4% (1 of 26), and 27% (7 of 26) of patients achieved stable disease.",Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971935/),%,4,5112,DB02701,Nicotinamide
up to,20521052,maximum sorafenib concentrations (t(max)),"Mean changes observed after 1 cycle in BP (n = 31) and HR (n = 30) at maximum sorafenib concentrations (t(max)) were moderate (up to 11.7 mm Hg and -6.6 bpm, respectively).",A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521052/),hg·mm,11.7,6335,DB02701,Nicotinamide
,20521052,maximum sorafenib concentrations (t(max)),"Mean changes observed after 1 cycle in BP (n = 31) and HR (n = 30) at maximum sorafenib concentrations (t(max)) were moderate (up to 11.7 mm Hg and -6.6 bpm, respectively).",A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521052/),bpm,-,6336,DB02701,Nicotinamide
,20521052,maximum sorafenib concentrations (t(max)),"Mean changes observed after 1 cycle in BP (n = 31) and HR (n = 30) at maximum sorafenib concentrations (t(max)) were moderate (up to 11.7 mm Hg and -6.6 bpm, respectively).",A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20521052/),bpm,6.6,6337,DB02701,Nicotinamide
,32274565,AUC(0-12 h),"Once weekly, high-dose sorafenib exposure was escalated up to a target AUC(0-12 h) of 125-150 mg/L/h, achieving a twofold higher Cmax compared to standard continuous dosing.","Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32274565/),[mg] / [h·l],125-150,7203,DB02701,Nicotinamide
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],72.38,8744,DB02701,Nicotinamide
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],49.15,8745,DB02701,Nicotinamide
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],178.65,8746,DB02701,Nicotinamide
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],109.31,8747,DB02701,Nicotinamide
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],332.81,8748,DB02701,Nicotinamide
,28614959,Cmax,"The results showed that the Cmax (low dose: 72.38 ± 8.76 versus 49.15 ± 5.46 ng/mL; medium dose: 178.65 ± 21.05 versus 109.31 ± 14.17 ng/mL; high dose: 332.81 ± 29.38 versus 230.86 ± 9.68 ng/mL) of sorafenib at different doses increased significantly with the pretreatment of triptolide, and while the oral clearance rate of sorafenib decreased.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[ng] / [ml],230.86,8749,DB02701,Nicotinamide
,28614959,t1/2,The t1/2 of sorafenib increased significant (p < 0.05) from 9.02 ± 1.16 to 12.17 ± 2.95 h at low dose with the pretreatment of triptolide.,The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),h,9.02,8750,DB02701,Nicotinamide
,28614959,t1/2,The t1/2 of sorafenib increased significant (p < 0.05) from 9.02 ± 1.16 to 12.17 ± 2.95 h at low dose with the pretreatment of triptolide.,The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),h,12.17,8751,DB02701,Nicotinamide
,28614959,intrinsic clearance rate,"However, triptolide could significantly decrease the intrinsic clearance rate of sorafenib from 51.7 ± 6.37 to 32.4 ± 4.43 μL/min/mg protein in rat liver microsomes.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[μl] / [mg·min],51.7,8752,DB02701,Nicotinamide
,28614959,intrinsic clearance rate,"However, triptolide could significantly decrease the intrinsic clearance rate of sorafenib from 51.7 ± 6.37 to 32.4 ± 4.43 μL/min/mg protein in rat liver microsomes.",The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28614959/),[μl] / [mg·min],32.4,8753,DB02701,Nicotinamide
greater,9165139,peak concentrations,In all patients peak concentrations greater than 700 nmol/ml could be obtained 0.25-3 h (mean 0.83 +/- 0.73 h) after drug intake.,"Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165139/),[nM] / [ml],700,12189,DB02701,Nicotinamide
above,9165139,Peak plasma concentrations,Peak plasma concentrations above the 700 nmol/ml level were obtained in all patients but these concentrations could not be reproduced during the entire course of the treatment in a significant portion of the subjects.,"Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165139/),[nM] / [ml],700,12190,DB02701,Nicotinamide
,29092654,metabolic ratios,"3. The metabolic ratios of O-desmethyltramadol, the product of CYP2D-mediated metabolism of tramadol, in normal and diabetic control rats were found to be 0.33 ± 0.12 and 0.29 ± 0.07, respectively.","Changes in CYP2D enzyme activity following induction of type 2 diabetes, and administration of cinnamon and metformin: an experimental animal study. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29092654/),,0.33,12391,DB02701,Nicotinamide
,29092654,metabolic ratios,"3. The metabolic ratios of O-desmethyltramadol, the product of CYP2D-mediated metabolism of tramadol, in normal and diabetic control rats were found to be 0.33 ± 0.12 and 0.29 ± 0.07, respectively.","Changes in CYP2D enzyme activity following induction of type 2 diabetes, and administration of cinnamon and metformin: an experimental animal study. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29092654/),,0.29,12392,DB02701,Nicotinamide
,24786603,Tmax,Tmax of both TMZ and AIC was delayed from 0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb).,Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),h,0.75,12948,DB02701,Nicotinamide
,24786603,Tmax,Tmax of both TMZ and AIC was delayed from 0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb).,Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),h,1.5,12949,DB02701,Nicotinamide
,24786603,progression-free survival,"The median progression-free survival was 7.9 months (95% confidence interval (CI): 5.4-14.55), and the median overall survival was 17.8 months (95% CI: 14.7-25.6).",Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),month,7.9,12950,DB02701,Nicotinamide
,24786603,overall survival,"The median progression-free survival was 7.9 months (95% confidence interval (CI): 5.4-14.55), and the median overall survival was 17.8 months (95% CI: 14.7-25.6).",Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786603/),month,17.8,12951,DB02701,Nicotinamide
,28465443,overall response rate,"The overall response rate in 24 evaluable patients at all 4 dose levels was 21% [95% confidence interval (CI), 7.1-42.2], and 25% (95% CI, 8.7-49.1) in patients with measureable disease.",Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28465443/),%,21,13170,DB02701,Nicotinamide
,28465443,overall response rate,"The overall response rate in 24 evaluable patients at all 4 dose levels was 21% [95% confidence interval (CI), 7.1-42.2], and 25% (95% CI, 8.7-49.1) in patients with measureable disease.",Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28465443/),%,25,13171,DB02701,Nicotinamide
,28465443,progression-free survival (PFS),"Median progression-free survival (PFS) for 24 patients evaluable for PFS was 3.8 months (95% CI, 3.2-5.6 months); median overall survival was 15.5 months (95% CI, 8.5-26.3 months).",Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28465443/),month,3.8,13172,DB02701,Nicotinamide
,28465443,overall survival,"Median progression-free survival (PFS) for 24 patients evaluable for PFS was 3.8 months (95% CI, 3.2-5.6 months); median overall survival was 15.5 months (95% CI, 8.5-26.3 months).",Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28465443/),month,15.5,13173,DB02701,Nicotinamide
,22666367,AUC,"On day 28, median sorafenib AUC (n = 17) was significantly higher in sarcopenic patients (102.4 mg/l.h versus 53.7 mg/l.h, p = 0.013).",Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22666367/),[mg] / [h·l],102.4,14713,DB02701,Nicotinamide
,22666367,AUC,"On day 28, median sorafenib AUC (n = 17) was significantly higher in sarcopenic patients (102.4 mg/l.h versus 53.7 mg/l.h, p = 0.013).",Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22666367/),[mg] / [h·l],53.7,14714,DB02701,Nicotinamide
,1296704,relative bioavailability,"From the results obtained, we have seen that both the 2 products of 10 mg (A and B) and the 2 products of 20 mg (C and D) are equivalent and have high relative bioavailability: it reaches the values of 96.5% (A versus B) and 120% (C versus D).",[The bioavailability of nicorandil after oral administration of a single dose of 10 or 20 mg preparations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1296704/),%,96.5,18647,DB02701,Nicotinamide
,1296704,relative bioavailability,"From the results obtained, we have seen that both the 2 products of 10 mg (A and B) and the 2 products of 20 mg (C and D) are equivalent and have high relative bioavailability: it reaches the values of 96.5% (A versus B) and 120% (C versus D).",[The bioavailability of nicorandil after oral administration of a single dose of 10 or 20 mg preparations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1296704/),%,120,18648,DB02701,Nicotinamide
,10509758,peak serum concentrations,"6AN reached peak serum concentrations of 80-90 microM and was cleared rapidly, with T1/2alpha and T1/2beta values of 7.4 and 31.3 min, respectively.","Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10509758/),μM,80-90,20523,DB02701,Nicotinamide
,10509758,T1/2alpha,"6AN reached peak serum concentrations of 80-90 microM and was cleared rapidly, with T1/2alpha and T1/2beta values of 7.4 and 31.3 min, respectively.","Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10509758/),min,7.4,20524,DB02701,Nicotinamide
,10509758,T1/2beta,"6AN reached peak serum concentrations of 80-90 microM and was cleared rapidly, with T1/2alpha and T1/2beta values of 7.4 and 31.3 min, respectively.","Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10509758/),min,31.3,20525,DB02701,Nicotinamide
,10509758,Bioavailability,Bioavailability was 80-100% with identical plasma pharmacokinetics after i.p. administration.,"Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10509758/),%,80-100,20526,DB02701,Nicotinamide
,8263109,detection limit,"We developed a simple, specific, sensitive, and precise high-performance liquid chromatographic method for the determination of nicorandil in aqueous solution and rat plasma, achieving a detection limit of 0.3 microgram/ml with 180-microliters samples.",High-performance liquid chromatographic method for stability and pharmacokinetic studies of nicorandil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263109/),[μg] / [ml],0.3,21100,DB02701,Nicotinamide
,8263109,half-life,Nicorandil was found to be relatively stable between pH 2 and 10 at 37 degrees C (half-life = 461-84 h) and it is subjected to specific base catalysis above pH 10.,High-performance liquid chromatographic method for stability and pharmacokinetic studies of nicorandil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263109/),h,461-84,21101,DB02701,Nicotinamide
,26477611,AUC(N-oxide,"When patients were classified by cut-off points (AUC(N-oxide:) 2.0 μg ∙ day/mL, AUC ratio: 0.13), progression-free survival was significantly longer in patients with AUC(N-oxide) ≤ 2.0 μg ∙ day/mL (P = 0.0048, log-rank test).",Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26477611/),[d·μg·∙] / [ml],2.0,21308,DB02701,Nicotinamide
,26477611,AUC ratio,"When patients were classified by cut-off points (AUC(N-oxide:) 2.0 μg ∙ day/mL, AUC ratio: 0.13), progression-free survival was significantly longer in patients with AUC(N-oxide) ≤ 2.0 μg ∙ day/mL (P = 0.0048, log-rank test).",Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26477611/),,0.13,21309,DB02701,Nicotinamide
≤,26477611,AUC(N-oxide),"When patients were classified by cut-off points (AUC(N-oxide:) 2.0 μg ∙ day/mL, AUC ratio: 0.13), progression-free survival was significantly longer in patients with AUC(N-oxide) ≤ 2.0 μg ∙ day/mL (P = 0.0048, log-rank test).",Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26477611/),[d·μg·∙] / [ml],2.0,21310,DB02701,Nicotinamide
,23673446,serum trough concentrations,"At this time, serum trough concentrations of sorafenib and M-2 were at 5.9 and 1.1 μg/ml, respectively.",Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23673446/),[μg] / [ml],5.9,22685,DB02701,Nicotinamide
,23673446,serum trough concentrations,"At this time, serum trough concentrations of sorafenib and M-2 were at 5.9 and 1.1 μg/ml, respectively.",Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23673446/),[μg] / [ml],1.1,22686,DB02701,Nicotinamide
,3943086,survival times,"The mean survival times for the control and FUra-treated mice (5 mg/kg at 1, 3, 5, and 7 days after tumor cell inoculation) were 9.7 and 12.4 days, respectively.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,9.7,24816,DB02701,Nicotinamide
,3943086,survival times,"The mean survival times for the control and FUra-treated mice (5 mg/kg at 1, 3, 5, and 7 days after tumor cell inoculation) were 9.7 and 12.4 days, respectively.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,12.4,24817,DB02701,Nicotinamide
,3943086,survival time,"When BVUra (200 mumol/kg) was administered 1 h before each injection of FUra, the mean survival time was extended to 17.1 days.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,17.1,24818,DB02701,Nicotinamide
,3943086,survival time,"When the dose of FUra was increased to 20 mg/kg, the mean survival time was 15.3 days; upon a preceding injection of BVUra the mean survival time decreased to 9.2 days.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,15.3,24819,DB02701,Nicotinamide
,3943086,survival time,"When the dose of FUra was increased to 20 mg/kg, the mean survival time was 15.3 days; upon a preceding injection of BVUra the mean survival time decreased to 9.2 days.",Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943086/),d,9.2,24820,DB02701,Nicotinamide
,28069720,renal clearance,"1-NMN renal clearance was higher in both mid (504 ± 293 ml/min, P < 0.01) and late pregnancy (557 ± 305 ml/min, P < 0.01) compared with postpartum (240 ± 106 ml/min).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],504,25697,DB02701,Nicotinamide
,28069720,renal clearance,"1-NMN renal clearance was higher in both mid (504 ± 293 ml/min, P < 0.01) and late pregnancy (557 ± 305 ml/min, P < 0.01) compared with postpartum (240 ± 106 ml/min).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],557,25698,DB02701,Nicotinamide
,28069720,renal clearance,"1-NMN renal clearance was higher in both mid (504 ± 293 ml/min, P < 0.01) and late pregnancy (557 ± 305 ml/min, P < 0.01) compared with postpartum (240 ± 106 ml/min).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],240,25699,DB02701,Nicotinamide
,28069720,renal secretion,"The renal secretion of 1-NMN was 3.5-fold higher in mid pregnancy (269± 267, P < 0.05) and 4.5-fold higher in late pregnancy compared with postpartum (342 ± 283 versus 76 ± 92 ml/min, P < 0.01).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],269,25700,DB02701,Nicotinamide
,28069720,renal secretion,"The renal secretion of 1-NMN was 3.5-fold higher in mid pregnancy (269± 267, P < 0.05) and 4.5-fold higher in late pregnancy compared with postpartum (342 ± 283 versus 76 ± 92 ml/min, P < 0.01).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],342,25701,DB02701,Nicotinamide
,28069720,renal secretion,"The renal secretion of 1-NMN was 3.5-fold higher in mid pregnancy (269± 267, P < 0.05) and 4.5-fold higher in late pregnancy compared with postpartum (342 ± 283 versus 76 ± 92 ml/min, P < 0.01).","Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069720/),[ml] / [min],76,25702,DB02701,Nicotinamide
,22752248,overall survival,Median overall survival was 25.2 months.,Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752248/),month,25.2,27315,DB02701,Nicotinamide
,21392074,clearance,"PK model parameter estimates (range) for an 80 kg patient were clearance 8.13 l h(-1) (3.6-22.3 l h(-1) ), volume 213 l (50-1000 l), mean absorption transit time 1.98 h (0.5-13 h), fraction undergoing EHC 50% and average time to gall bladder emptying 6.13 h.",Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392074/),[l] / [h],8.13,31008,DB02701,Nicotinamide
,21392074,volume,"PK model parameter estimates (range) for an 80 kg patient were clearance 8.13 l h(-1) (3.6-22.3 l h(-1) ), volume 213 l (50-1000 l), mean absorption transit time 1.98 h (0.5-13 h), fraction undergoing EHC 50% and average time to gall bladder emptying 6.13 h.",Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392074/),l,213,31009,DB02701,Nicotinamide
,21392074,absorption transit time,"PK model parameter estimates (range) for an 80 kg patient were clearance 8.13 l h(-1) (3.6-22.3 l h(-1) ), volume 213 l (50-1000 l), mean absorption transit time 1.98 h (0.5-13 h), fraction undergoing EHC 50% and average time to gall bladder emptying 6.13 h.",Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392074/),h,1.98,31010,DB02701,Nicotinamide
,21392074,time to gall bladder emptying,"PK model parameter estimates (range) for an 80 kg patient were clearance 8.13 l h(-1) (3.6-22.3 l h(-1) ), volume 213 l (50-1000 l), mean absorption transit time 1.98 h (0.5-13 h), fraction undergoing EHC 50% and average time to gall bladder emptying 6.13 h.",Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392074/),h,6.13,31011,DB02701,Nicotinamide
,32436621,metabolic response rate,The metabolic response rate in FDG-PET was 17% on day 5 and 20% on day 14.,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),%,17,31814,DB02701,Nicotinamide
,32436621,metabolic response rate,The metabolic response rate in FDG-PET was 17% on day 5 and 20% on day 14.,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),%,20,31815,DB02701,Nicotinamide
,32436621,progression free survival (PFS),"Median progression free survival (PFS) and overall survival (OS) were 3.25 and 5.85 months, respectively.",Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),month,3.25,31816,DB02701,Nicotinamide
,32436621,overall survival (OS),"Median progression free survival (PFS) and overall survival (OS) were 3.25 and 5.85 months, respectively.",Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),month,5.85,31817,DB02701,Nicotinamide
,29563636,TTP,Phase-II: patients (N = 93) were randomised to nintedanib (n = 62) or sorafenib (n = 31); TTP was 5.5 vs.,"A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29563636/),,5.5,33221,DB02701,Nicotinamide
,28153597,bioavailability,"The bioavailability of MNA administered as MNANO3 equaled 22.4% as compared to MNANO2 or MNACl (9.2% and 9.1%, respectively).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),%,22.4,33816,DB02701,Nicotinamide
,28153597,bioavailability,"The bioavailability of MNA administered as MNANO3 equaled 22.4% as compared to MNANO2 or MNACl (9.2% and 9.1%, respectively).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),%,9.2,33817,DB02701,Nicotinamide
,28153597,bioavailability,"The bioavailability of MNA administered as MNANO3 equaled 22.4% as compared to MNANO2 or MNACl (9.2% and 9.1%, respectively).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),%,9.1,33818,DB02701,Nicotinamide
,28153597,tmax,"In turn, tmax was the shortest and Cmax the highest (0.22 h and 56.65μM) for intragastrically administered MNANO2 comparing to MNANO3 (1.92 h, 21.74μM) or MNACl (0.63 h, 16.13μM).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),h,0.22,33819,DB02701,Nicotinamide
,28153597,tmax,"In turn, tmax was the shortest and Cmax the highest (0.22 h and 56.65μM) for intragastrically administered MNANO2 comparing to MNANO3 (1.92 h, 21.74μM) or MNACl (0.63 h, 16.13μM).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),h,1.92,33820,DB02701,Nicotinamide
,28153597,tmax,"In turn, tmax was the shortest and Cmax the highest (0.22 h and 56.65μM) for intragastrically administered MNANO2 comparing to MNANO3 (1.92 h, 21.74μM) or MNACl (0.63 h, 16.13μM).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),h,0.63,33821,DB02701,Nicotinamide
,28153597,Cmax,"In turn, tmax was the shortest and Cmax the highest (0.22 h and 56.65μM) for intragastrically administered MNANO2 comparing to MNANO3 (1.92 h, 21.74μM) or MNACl (0.63 h, 16.13μM).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),μM,56.65,33822,DB02701,Nicotinamide
,28153597,Cmax,"In turn, tmax was the shortest and Cmax the highest (0.22 h and 56.65μM) for intragastrically administered MNANO2 comparing to MNANO3 (1.92 h, 21.74μM) or MNACl (0.63 h, 16.13μM).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),h,1.92,33823,DB02701,Nicotinamide
,28153597,Cmax,"In turn, tmax was the shortest and Cmax the highest (0.22 h and 56.65μM) for intragastrically administered MNANO2 comparing to MNANO3 (1.92 h, 21.74μM) or MNACl (0.63 h, 16.13μM).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),μM,21.74,33824,DB02701,Nicotinamide
,28153597,Cmax,"In turn, tmax was the shortest and Cmax the highest (0.22 h and 56.65μM) for intragastrically administered MNANO2 comparing to MNANO3 (1.92 h, 21.74μM) or MNACl (0.63 h, 16.13μM).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),h,0.63,33825,DB02701,Nicotinamide
,28153597,Cmax,"In turn, tmax was the shortest and Cmax the highest (0.22 h and 56.65μM) for intragastrically administered MNANO2 comparing to MNANO3 (1.92 h, 21.74μM) or MNACl (0.63 h, 16.13μM).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),μM,16.13,33826,DB02701,Nicotinamide
,28153597,Transfer constant between central and peripheral compartments (kcp),"Transfer constant between central and peripheral compartments (kcp) and volume of distribution (Vss) for MNANO3 (0.33 h-1 and 1.96 L/kg) were higher as compared to MNANO2 or MNACl (0.11 h-1, 0.08 h-1 for kcp and 1.05 L/kg, 0.76 L/kg for Vss, respectively).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),1/[h],0.33,33827,DB02701,Nicotinamide
,28153597,Transfer constant between central and peripheral compartments (kcp),"Transfer constant between central and peripheral compartments (kcp) and volume of distribution (Vss) for MNANO3 (0.33 h-1 and 1.96 L/kg) were higher as compared to MNANO2 or MNACl (0.11 h-1, 0.08 h-1 for kcp and 1.05 L/kg, 0.76 L/kg for Vss, respectively).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),1/[h],0.11,33828,DB02701,Nicotinamide
,28153597,volume of distribution (Vss),"Transfer constant between central and peripheral compartments (kcp) and volume of distribution (Vss) for MNANO3 (0.33 h-1 and 1.96 L/kg) were higher as compared to MNANO2 or MNACl (0.11 h-1, 0.08 h-1 for kcp and 1.05 L/kg, 0.76 L/kg for Vss, respectively).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),[l] / [kg],1.96,33829,DB02701,Nicotinamide
,28153597,kcp,"Transfer constant between central and peripheral compartments (kcp) and volume of distribution (Vss) for MNANO3 (0.33 h-1 and 1.96 L/kg) were higher as compared to MNANO2 or MNACl (0.11 h-1, 0.08 h-1 for kcp and 1.05 L/kg, 0.76 L/kg for Vss, respectively).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),1/[h],0.08,33830,DB02701,Nicotinamide
,28153597,Vss,"Transfer constant between central and peripheral compartments (kcp) and volume of distribution (Vss) for MNANO3 (0.33 h-1 and 1.96 L/kg) were higher as compared to MNANO2 or MNACl (0.11 h-1, 0.08 h-1 for kcp and 1.05 L/kg, 0.76 L/kg for Vss, respectively).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),[l] / [kg],1.05,33831,DB02701,Nicotinamide
,28153597,Vss,"Transfer constant between central and peripheral compartments (kcp) and volume of distribution (Vss) for MNANO3 (0.33 h-1 and 1.96 L/kg) were higher as compared to MNANO2 or MNACl (0.11 h-1, 0.08 h-1 for kcp and 1.05 L/kg, 0.76 L/kg for Vss, respectively).",Pharmacokinetic Profile of 1-Methylnicotinamide Nitrate in Rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28153597/),[l] / [kg],0.76,33832,DB02701,Nicotinamide
,33068028,apparent total systemic clearance (CL),"Covariate exploration in the RA patient model revealed that estimated glomerular filtration rate (eGFR) and lymphocyte count had a significant effect on apparent total systemic clearance (CL), which was 91.7 L/h (2.3% relative standard error).",Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33068028/),[l] / [h],91.7,34947,DB02701,Nicotinamide
,33068028,area under plasma concentration-time curve,The simulated population mean area under plasma concentration-time curve for 24 hours after dosing showed a 1.35-fold increase in patients with severe renal impairment (eGFR 22.5 mL/min/1.73m2 ) compared with patients with reference eGFR (91.5 mL/min/1.73m2 ).,Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33068028/),m,91.5,34948,DB02701,Nicotinamide
,24365125,Objective response rates,Objective response rates were 29% (trebananib plus sorafenib) and 53% (trebananib plus sunitinib).,"A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365125/),%,29,35087,DB02701,Nicotinamide
,24365125,Objective response rates,Objective response rates were 29% (trebananib plus sorafenib) and 53% (trebananib plus sunitinib).,"A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365125/),%,53,35088,DB02701,Nicotinamide
,22767146,overall disease control rate,"The overall disease control rate was 61% (95% confidence interval (CI): 42.6-78.8), including three confirmed responses (12%).",Sorafenib in advanced melanoma: a critical role for pharmacokinetics? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767146/),%,61,35637,DB02701,Nicotinamide
,34304009,m/z transitions,"Analysis was performed using an API 4000 QTRAP hybrid triple quadruple mass spectrometer and multiple reaction monitoring (MRM) in positive mode at m/z transitions of 159.100 → 90.00 and 162.200 → 117.200 for 5-AMQ and the internal standard, respectively.",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),,159.100,37809,DB02701,Nicotinamide
,34304009,m/z transitions,"Analysis was performed using an API 4000 QTRAP hybrid triple quadruple mass spectrometer and multiple reaction monitoring (MRM) in positive mode at m/z transitions of 159.100 → 90.00 and 162.200 → 117.200 for 5-AMQ and the internal standard, respectively.",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),,90.00,37810,DB02701,Nicotinamide
,34304009,m/z transitions,"Analysis was performed using an API 4000 QTRAP hybrid triple quadruple mass spectrometer and multiple reaction monitoring (MRM) in positive mode at m/z transitions of 159.100 → 90.00 and 162.200 → 117.200 for 5-AMQ and the internal standard, respectively.",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),,162.200,37811,DB02701,Nicotinamide
,34304009,m/z transitions,"Analysis was performed using an API 4000 QTRAP hybrid triple quadruple mass spectrometer and multiple reaction monitoring (MRM) in positive mode at m/z transitions of 159.100 → 90.00 and 162.200 → 117.200 for 5-AMQ and the internal standard, respectively.",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),,117.200,37812,DB02701,Nicotinamide
,34304009,extraction recoveries,"Furthermore, the extraction recoveries and matrix effects at three concentration levels of rat plasma samples ranged from 99.5 %-110.6 % and -6.1 %-14.1 %, respectively.",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),%,99.5,37813,DB02701,Nicotinamide
,34304009,extraction recoveries,"Furthermore, the extraction recoveries and matrix effects at three concentration levels of rat plasma samples ranged from 99.5 %-110.6 % and -6.1 %-14.1 %, respectively.",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),%,110.6,37814,DB02701,Nicotinamide
,34304009,maximum plasma concentration,"5-AMQ displayed substantial plasma exposures via IV and oral route, with a mean maximum plasma concentration of 2252 ng/mL after oral administration, mean area under the curve (AUC0-∞) of 3708 h.ng/mL and 14431 h.ng/mL for the IV and oral groups, respectively, mean terminal elimination half-life of 3.80 ± 1.10 h and 6.90 ± 1.20 h respectively after intravenous and oral dose, and a good oral bioavailability (F % = 38.4).",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),[ng] / [ml],2252,37815,DB02701,Nicotinamide
,34304009,area under the curve (AUC0-∞),"5-AMQ displayed substantial plasma exposures via IV and oral route, with a mean maximum plasma concentration of 2252 ng/mL after oral administration, mean area under the curve (AUC0-∞) of 3708 h.ng/mL and 14431 h.ng/mL for the IV and oral groups, respectively, mean terminal elimination half-life of 3.80 ± 1.10 h and 6.90 ± 1.20 h respectively after intravenous and oral dose, and a good oral bioavailability (F % = 38.4).",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),[h·ng] / [ml],3708,37816,DB02701,Nicotinamide
,34304009,area under the curve (AUC0-∞),"5-AMQ displayed substantial plasma exposures via IV and oral route, with a mean maximum plasma concentration of 2252 ng/mL after oral administration, mean area under the curve (AUC0-∞) of 3708 h.ng/mL and 14431 h.ng/mL for the IV and oral groups, respectively, mean terminal elimination half-life of 3.80 ± 1.10 h and 6.90 ± 1.20 h respectively after intravenous and oral dose, and a good oral bioavailability (F % = 38.4).",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),[h·ng] / [ml],14431,37817,DB02701,Nicotinamide
,34304009,terminal elimination half-life,"5-AMQ displayed substantial plasma exposures via IV and oral route, with a mean maximum plasma concentration of 2252 ng/mL after oral administration, mean area under the curve (AUC0-∞) of 3708 h.ng/mL and 14431 h.ng/mL for the IV and oral groups, respectively, mean terminal elimination half-life of 3.80 ± 1.10 h and 6.90 ± 1.20 h respectively after intravenous and oral dose, and a good oral bioavailability (F % = 38.4).",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),h,3.80,37818,DB02701,Nicotinamide
,34304009,terminal elimination half-life,"5-AMQ displayed substantial plasma exposures via IV and oral route, with a mean maximum plasma concentration of 2252 ng/mL after oral administration, mean area under the curve (AUC0-∞) of 3708 h.ng/mL and 14431 h.ng/mL for the IV and oral groups, respectively, mean terminal elimination half-life of 3.80 ± 1.10 h and 6.90 ± 1.20 h respectively after intravenous and oral dose, and a good oral bioavailability (F % = 38.4).",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),h,6.90,37819,DB02701,Nicotinamide
,34304009,oral bioavailability (F %,"5-AMQ displayed substantial plasma exposures via IV and oral route, with a mean maximum plasma concentration of 2252 ng/mL after oral administration, mean area under the curve (AUC0-∞) of 3708 h.ng/mL and 14431 h.ng/mL for the IV and oral groups, respectively, mean terminal elimination half-life of 3.80 ± 1.10 h and 6.90 ± 1.20 h respectively after intravenous and oral dose, and a good oral bioavailability (F % = 38.4).",Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304009/),,38.4,37820,DB02701,Nicotinamide
,1410588,half-life,"Plasma concentrations and clearance rates of the vitamin were found to be dose-dependent, with a half-life of approximately 7-9 h for the two highest doses administered (4 and 6 g), approximately 4 h with 2 g and approximately 1.5 h with a 1-g dose.","Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1410588/),h,7-9,40079,DB02701,Nicotinamide
,1410588,half-life,"Plasma concentrations and clearance rates of the vitamin were found to be dose-dependent, with a half-life of approximately 7-9 h for the two highest doses administered (4 and 6 g), approximately 4 h with 2 g and approximately 1.5 h with a 1-g dose.","Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1410588/),h,4,40080,DB02701,Nicotinamide
,1410588,half-life,"Plasma concentrations and clearance rates of the vitamin were found to be dose-dependent, with a half-life of approximately 7-9 h for the two highest doses administered (4 and 6 g), approximately 4 h with 2 g and approximately 1.5 h with a 1-g dose.","Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1410588/),h,1.5,40081,DB02701,Nicotinamide
,1410588,Peak concentrations,Peak concentrations ranged from 0.7 to 1.1 mumol.,"Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1410588/),μM,0.7 to 1.1,40082,DB02701,Nicotinamide
,1410588,time to reach peak plasma concentration,The time to reach peak plasma concentration was dose independent with a broad range from 0.73 to 3 h.,"Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1410588/),h,0.73 to 3,40083,DB02701,Nicotinamide
,9424008,enhancement ratios (ERs),"Irradiating tumours at peak times resulted in enhancement ratios (ERs) of 1.27 (C3H), 1.75 (KHT) and 1.45 (SCCVII) with high nicotinamide doses and 1.27 (C3H), 1.28 (KHT) and 1.36 (SCCVII) after giving clinically relevant doses (100-200 mg/kg).",Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9424008/),,1.27,40923,DB02701,Nicotinamide
,9424008,enhancement ratios (ERs),"Irradiating tumours at peak times resulted in enhancement ratios (ERs) of 1.27 (C3H), 1.75 (KHT) and 1.45 (SCCVII) with high nicotinamide doses and 1.27 (C3H), 1.28 (KHT) and 1.36 (SCCVII) after giving clinically relevant doses (100-200 mg/kg).",Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9424008/),,1.75,40924,DB02701,Nicotinamide
,9424008,enhancement ratios (ERs),"Irradiating tumours at peak times resulted in enhancement ratios (ERs) of 1.27 (C3H), 1.75 (KHT) and 1.45 (SCCVII) with high nicotinamide doses and 1.27 (C3H), 1.28 (KHT) and 1.36 (SCCVII) after giving clinically relevant doses (100-200 mg/kg).",Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9424008/),,1.45,40925,DB02701,Nicotinamide
,9424008,enhancement ratios (ERs),"Irradiating tumours at peak times resulted in enhancement ratios (ERs) of 1.27 (C3H), 1.75 (KHT) and 1.45 (SCCVII) with high nicotinamide doses and 1.27 (C3H), 1.28 (KHT) and 1.36 (SCCVII) after giving clinically relevant doses (100-200 mg/kg).",Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9424008/),,1.28,40926,DB02701,Nicotinamide
,9424008,enhancement ratios (ERs),"Irradiating tumours at peak times resulted in enhancement ratios (ERs) of 1.27 (C3H), 1.75 (KHT) and 1.45 (SCCVII) with high nicotinamide doses and 1.27 (C3H), 1.28 (KHT) and 1.36 (SCCVII) after giving clinically relevant doses (100-200 mg/kg).",Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9424008/),,1.36,40927,DB02701,Nicotinamide
,9424008,ERs,"Irradiating normal tissues at peak times after injecting 100-200 mg/kg nicotinamide gave ERs of 1.20 (skin), 0.90 (bladder) and 1.02 (lung).",Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9424008/),,1.20,40928,DB02701,Nicotinamide
,9424008,ERs,"Irradiating normal tissues at peak times after injecting 100-200 mg/kg nicotinamide gave ERs of 1.20 (skin), 0.90 (bladder) and 1.02 (lung).",Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9424008/),,0.90,40929,DB02701,Nicotinamide
,9424008,ERs,"Irradiating normal tissues at peak times after injecting 100-200 mg/kg nicotinamide gave ERs of 1.20 (skin), 0.90 (bladder) and 1.02 (lung).",Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9424008/),,1.02,40930,DB02701,Nicotinamide
,33283619,half-life,"On inoculating 2 mL of E. meliloti CGMCC 7333 (OD600 = 10) into soil containing 80 mg/kg flonicamid, 91.1% of the flonicamid was transformed within 9 d (half-life 2.6 d).",Biotransformation of flonicamid and sulfoxaflor by multifunctional bacterium Ensifer meliloti CGMCC 7333. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33283619/),d,2.6,41042,DB02701,Nicotinamide
,33283619,half-life,"On inoculating 2 mL of E. meliloti CGMCC 7333 (OD600 = 10) into soil containing 80 mg/kg sulfoxaflor, 83.9% of the sulfoxaflor was transformed within 9 d (half-life 3.4 d).",Biotransformation of flonicamid and sulfoxaflor by multifunctional bacterium Ensifer meliloti CGMCC 7333. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33283619/),d,3.4,41043,DB02701,Nicotinamide
,28983849,EE,Results showed that the average EE and DL of SRF-SLNs were 89.87 and 5.39%.,Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),%,89.87,41343,DB02701,Nicotinamide
,28983849,EE,Results showed that the average EE and DL of SRF-SLNs were 89.87 and 5.39%.,Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),%,5.39,41344,DB02701,Nicotinamide
,28983849,DL,Results showed that the average EE and DL of SRF-SLNs were 89.87 and 5.39%.,Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),%,5.39,41345,DB02701,Nicotinamide
,28983849,particle,"The average particle size, polydispersity index, and zeta potential of SRF-SLNs were 77.16 nm, 0.28, and - 18.1 mV, respectively.",Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),nm,77.16,41346,DB02701,Nicotinamide
,28983849,polydispersity index,"The average particle size, polydispersity index, and zeta potential of SRF-SLNs were 77.16 nm, 0.28, and - 18.1 mV, respectively.",Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),mv,0.28,41347,DB02701,Nicotinamide
,28983849,zeta potential,"The average particle size, polydispersity index, and zeta potential of SRF-SLNs were 77.16 nm, 0.28, and - 18.1 mV, respectively.",Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),mv,-,41348,DB02701,Nicotinamide
,28983849,zeta potential,"The average particle size, polydispersity index, and zeta potential of SRF-SLNs were 77.16 nm, 0.28, and - 18.1 mV, respectively.",Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28983849/),mv,18.1,41349,DB02701,Nicotinamide
,2973003,recovery,"1 microgram of TR/ml of blood serum, recovery approx. 76%.",A spectrophotometric method for N-nicotinoyl-tryptamine (tryptamide) assay in the blood serum of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2973003/),%,76,43468,DB02701,Nicotinamide
,30503942,IC50,"The ureido analogue 6u emerged as the most potent multikinase inhibitor in the ureido series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.18, 0.23 and 0.10 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.18,46174,DB02701,Nicotinamide
,30503942,IC50,"The ureido analogue 6u emerged as the most potent multikinase inhibitor in the ureido series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.18, 0.23 and 0.10 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.23,46175,DB02701,Nicotinamide
,30503942,IC50,"The ureido analogue 6u emerged as the most potent multikinase inhibitor in the ureido series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.18, 0.23 and 0.10 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.10,46176,DB02701,Nicotinamide
,30503942,IC50,"Whereas, the amido congener 10j emerged as the most potent multikinase inhibitor in the amide series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.28, 0.46 and 0.09 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.28,46177,DB02701,Nicotinamide
,30503942,IC50,"Whereas, the amido congener 10j emerged as the most potent multikinase inhibitor in the amide series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.28, 0.46 and 0.09 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.46,46178,DB02701,Nicotinamide
,30503942,IC50,"Whereas, the amido congener 10j emerged as the most potent multikinase inhibitor in the amide series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.28, 0.46 and 0.09 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.09,46179,DB02701,Nicotinamide
,30503942,IC50,"While, indolinone 6u was the most potent derivative towards HepG2 cells (IC50 = 2.67 ± 0.14 μM), 6r stood out as the most potent indolinone against A498 cells (IC50 = 0.78 ± 0.02 μM).","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,2.67,46180,DB02701,Nicotinamide
,30503942,IC50,"While, indolinone 6u was the most potent derivative towards HepG2 cells (IC50 = 2.67 ± 0.14 μM), 6r stood out as the most potent indolinone against A498 cells (IC50 = 0.78 ± 0.02 μM).","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.78,46181,DB02701,Nicotinamide
,32881002,flow rate,The flow rate was 0.3 mL/min.,A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32881002/),[ml] / [min],0.3,47051,DB02701,Nicotinamide
,32881002,m/z,"A TSQ triple quadrupole mass spectrometer operated in positive-ion mode was used for mass detection, with multiple reaction monitoring transitions of m/z 503.3 > 459.1 and m/z 435.3 > 367.1 for LXH254 and olaparib (internal standard), respectively.",A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32881002/),,503.3,47052,DB02701,Nicotinamide
>,32881002,m/z,"A TSQ triple quadrupole mass spectrometer operated in positive-ion mode was used for mass detection, with multiple reaction monitoring transitions of m/z 503.3 > 459.1 and m/z 435.3 > 367.1 for LXH254 and olaparib (internal standard), respectively.",A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32881002/),,459.1,47053,DB02701,Nicotinamide
>,32881002,m/z,"A TSQ triple quadrupole mass spectrometer operated in positive-ion mode was used for mass detection, with multiple reaction monitoring transitions of m/z 503.3 > 459.1 and m/z 435.3 > 367.1 for LXH254 and olaparib (internal standard), respectively.",A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32881002/),,435.3,47054,DB02701,Nicotinamide
>,32881002,m/z,"A TSQ triple quadrupole mass spectrometer operated in positive-ion mode was used for mass detection, with multiple reaction monitoring transitions of m/z 503.3 > 459.1 and m/z 435.3 > 367.1 for LXH254 and olaparib (internal standard), respectively.",A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32881002/),,367.1,47055,DB02701,Nicotinamide
more,32881002,recovery,The mean recovery was more than 78.55%.,A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32881002/),%,78.55,47056,DB02701,Nicotinamide
,32881002,bioavailability,"The pharmacokinetic study revealed that LXH254 showed low clearance, moderate bioavailability (~30%), and linear pharmacokinetic profile over the oral dose range of 2-15 mg/kg.",A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32881002/),%,30,47057,DB02701,Nicotinamide
,27632696,critical micelle concentration,"PAAssVES was found to self-assemble into nanomicelles with diameter of about 130 nm, and a critical micelle concentration of about 6.3 μg/mL.",In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid) -cystamine hydrochloride-D-α-tocopherol succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632696/),[μg] / [ml],6.3,48128,DB02701,Nicotinamide
,26709621,oral bioavailability,"However, the oral bioavailability of sorafenib tablet (Nexavar) is merely 38-49% relative to the oral solution, due to the low aqueous solubility of sorafenib and its relatively high daily dose.","Improving Oral Bioavailability of Sorafenib by Optimizing the ""Spring"" and ""Parachute"" Based on Molecular Interaction Mechanisms. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709621/),%,38-49,49008,DB02701,Nicotinamide
,7599052,Cpeak,"The mean Cpeak values were 82, 115 and 150 micrograms ml-1 for NCT doses of 4, 5 and 6 g respectively and were dose dependent.",Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599052/),[μg] / [ml],82,50289,DB02701,Nicotinamide
,7599052,Cpeak,"The mean Cpeak values were 82, 115 and 150 micrograms ml-1 for NCT doses of 4, 5 and 6 g respectively and were dose dependent.",Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599052/),[μg] / [ml],115,50290,DB02701,Nicotinamide
,7599052,Cpeak,"The mean Cpeak values were 82, 115 and 150 micrograms ml-1 for NCT doses of 4, 5 and 6 g respectively and were dose dependent.",Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599052/),[μg] / [ml],150,50291,DB02701,Nicotinamide
,7599052,time of Cpeak,The time of Cpeak was independent of dose with an overall mean of 2.4 h (range 0.7-4 h).,Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599052/),h,2.4,50292,DB02701,Nicotinamide
above,7818933,peak plasma levels (Cmax),Pharmacokinetic analysis showed peak plasma levels (Cmax) above 100 mg/l 45 minutes after the administration of both doses.,Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818933/),[mg] / [l],100,53112,DB02701,Nicotinamide
,7818933,thermal half life,This was followed by a biexponential decay of plasma concentrations with a thermal half life of 9.4h.,Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818933/),h,9.4,53113,DB02701,Nicotinamide
,22872523,objective response rate,The objective response rate was 56 % among patients with measurable disease at baseline who received motesanib in combination with taxane-based chemotherapy.,Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22872523/),%,56,53291,DB02701,Nicotinamide
,22872523,objective response rate,The objective response rate of 56 % suggests a potential benefit of motesanib in combination with taxane-based chemotherapy.,Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22872523/),%,56,53292,DB02701,Nicotinamide
,28210753,half-life,"In the pharmacokinetic study, puerarin-7-O-glucuronide was cleared with a half-life of 0.94 h after intravenous administration.","Puerarin-7-O-glucuronide, a water-soluble puerarin metabolite, prevents angiotensin II-induced cardiomyocyte hypertrophy by reducing oxidative stress. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28210753/),h,0.94,55555,DB02701,Nicotinamide
,26299424,absolute oral bioavailability,"The absolute oral bioavailability of pristimerin is 28.4% at a dose of 1 mg·kg(-1), and the bioavailability was poor.",Absorption and metabolism characteristics of pristimerin as determined by a sensitive and reliable LC-MS/MS method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26299424/),%,28.4,56116,DB02701,Nicotinamide
,26299424,half-life,"Pristimerin was stable in S9 fractions but metabolized in HLM with a half-life of 20.4 min, which indicated that pristimerin could be mainly metabolized by phase I enzymes.",Absorption and metabolism characteristics of pristimerin as determined by a sensitive and reliable LC-MS/MS method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26299424/),min,20.4,56117,DB02701,Nicotinamide
,32322425,relative bioavailability,"The relative bioavailability of NAR-NCT was 175.09% of NAR, Cmax was 8.43 and 2.06 times of NAR and NAR + NCT, respectively, Tmax was advanced from 0.49 h to 0.09 h, CL was decreased from 91.1 L/h/kg to 49.1 L/h/kg, and t 1/2 was increased from 5.37 h to 8.24 h, highlighting its rapid absorption and slow elimination.",Pharmacokinetic Comparisons of Naringenin and Naringenin-Nicotinamide Cocrystal in Rats by LC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322425/),%,175.09,59861,DB02701,Nicotinamide
,32322425,Tmax,"The relative bioavailability of NAR-NCT was 175.09% of NAR, Cmax was 8.43 and 2.06 times of NAR and NAR + NCT, respectively, Tmax was advanced from 0.49 h to 0.09 h, CL was decreased from 91.1 L/h/kg to 49.1 L/h/kg, and t 1/2 was increased from 5.37 h to 8.24 h, highlighting its rapid absorption and slow elimination.",Pharmacokinetic Comparisons of Naringenin and Naringenin-Nicotinamide Cocrystal in Rats by LC-MS/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322425/),h,0.49,59862,DB02701,Nicotinamide
,32322425,Tmax,"The relative bioavailability of NAR-NCT was 175.09% of NAR, Cmax was 8.43 and 2.06 times of NAR and NAR + NCT, respectively, Tmax was advanced from 0.49 h to 0.09 h, CL was decreased from 91.1 L/h/kg to 49.1 L/h/kg, and t 1/2 was increased from 5.37 h to 8.24 h, highlighting its rapid absorption and slow elimination.",Pharmacokinetic Comparisons of Naringenin and Naringenin-Nicotinamide Cocrystal in Rats by LC-MS/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322425/),h,0.09,59863,DB02701,Nicotinamide
,32322425,CL,"The relative bioavailability of NAR-NCT was 175.09% of NAR, Cmax was 8.43 and 2.06 times of NAR and NAR + NCT, respectively, Tmax was advanced from 0.49 h to 0.09 h, CL was decreased from 91.1 L/h/kg to 49.1 L/h/kg, and t 1/2 was increased from 5.37 h to 8.24 h, highlighting its rapid absorption and slow elimination.",Pharmacokinetic Comparisons of Naringenin and Naringenin-Nicotinamide Cocrystal in Rats by LC-MS/MS. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322425/),[l] / [h·kg],91.1,59864,DB02701,Nicotinamide
,32322425,CL,"The relative bioavailability of NAR-NCT was 175.09% of NAR, Cmax was 8.43 and 2.06 times of NAR and NAR + NCT, respectively, Tmax was advanced from 0.49 h to 0.09 h, CL was decreased from 91.1 L/h/kg to 49.1 L/h/kg, and t 1/2 was increased from 5.37 h to 8.24 h, highlighting its rapid absorption and slow elimination.",Pharmacokinetic Comparisons of Naringenin and Naringenin-Nicotinamide Cocrystal in Rats by LC-MS/MS. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322425/),[l] / [h·kg],49.1,59865,DB02701,Nicotinamide
,32322425,t 1/2,"The relative bioavailability of NAR-NCT was 175.09% of NAR, Cmax was 8.43 and 2.06 times of NAR and NAR + NCT, respectively, Tmax was advanced from 0.49 h to 0.09 h, CL was decreased from 91.1 L/h/kg to 49.1 L/h/kg, and t 1/2 was increased from 5.37 h to 8.24 h, highlighting its rapid absorption and slow elimination.",Pharmacokinetic Comparisons of Naringenin and Naringenin-Nicotinamide Cocrystal in Rats by LC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322425/),h,5.37,59866,DB02701,Nicotinamide
,32322425,t 1/2,"The relative bioavailability of NAR-NCT was 175.09% of NAR, Cmax was 8.43 and 2.06 times of NAR and NAR + NCT, respectively, Tmax was advanced from 0.49 h to 0.09 h, CL was decreased from 91.1 L/h/kg to 49.1 L/h/kg, and t 1/2 was increased from 5.37 h to 8.24 h, highlighting its rapid absorption and slow elimination.",Pharmacokinetic Comparisons of Naringenin and Naringenin-Nicotinamide Cocrystal in Rats by LC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32322425/),h,8.24,59867,DB02701,Nicotinamide
,22961690,AUC(0-12 hours) at steady-state,"At 80 mg/m(2) /dose, the median AUC(0-12 hours) at steady-state was 39.5 µg hours/ml.",Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22961690/),[h·μg] / [ml],39.5,60709,DB02701,Nicotinamide
,22927483,N-oxide metabolite ratio,Mean sorafenib N-oxide metabolite ratio was 0.27 ± 0.14.,Ontogeny and sorafenib metabolism. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22927483/),,0.27,62375,DB02701,Nicotinamide
,22927483,N-oxide ratios,"In children of ≤10 years of age, boys had approximately 2-fold higher N-oxide ratios than girls (0.40 ± 0.15 vs. 0.22 ± 0.12, P = 0.026).",Ontogeny and sorafenib metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22927483/),,0.40,62376,DB02701,Nicotinamide
,22927483,N-oxide ratios,"In children of ≤10 years of age, boys had approximately 2-fold higher N-oxide ratios than girls (0.40 ± 0.15 vs. 0.22 ± 0.12, P = 0.026).",Ontogeny and sorafenib metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22927483/),,0.22,62377,DB02701,Nicotinamide
,25986538,tmax,"[(14)C]ASP015K was rapidly absorbed with tmax of 1.6 and 1.8 h for ASP015K and total radioactivity in plasma, respectively.","Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25986538/),h,1.6,63891,DB02701,Nicotinamide
,25986538,tmax,"[(14)C]ASP015K was rapidly absorbed with tmax of 1.6 and 1.8 h for ASP015K and total radioactivity in plasma, respectively.","Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25986538/),h,1.8,63892,DB02701,Nicotinamide
,25986538,recovery,"Mean recovery in urine and feces amounted to 36.8% and 56.6% of the administered dose, respectively.","Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25986538/),%,36.8,63893,DB02701,Nicotinamide
,25986538,recovery,"Mean recovery in urine and feces amounted to 36.8% and 56.6% of the administered dose, respectively.","Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25986538/),%,56.6,63894,DB02701,Nicotinamide
,32588123,concentration,The median sorafenib concentration was 2.91 μg/mL (range 0.74-8.8 μg/mL).,Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32588123/),[μg] / [ml],2.91,65117,DB02701,Nicotinamide
,32588123,trough concentration,"From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40-3.45 μg/mL in patients with HCC.",Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32588123/),[μg] / [ml],1.40-3.45,65118,DB02701,Nicotinamide
,27992451,response rate,The response rate was 30%.,Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27992451/),%,30,67410,DB02701,Nicotinamide
,27909950,overall survival (OS),"Median overall survival (OS), progression-free survival, and time to progression (TTP) were 8.6, 2.7, and 3.8 months, respectively.","HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),month,8.6,69691,DB02701,Nicotinamide
,27909950,progression-free survival,"Median overall survival (OS), progression-free survival, and time to progression (TTP) were 8.6, 2.7, and 3.8 months, respectively.","HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),month,2.7,69692,DB02701,Nicotinamide
,27909950,time to progression (TTP),"Median overall survival (OS), progression-free survival, and time to progression (TTP) were 8.6, 2.7, and 3.8 months, respectively.","HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),month,3.8,69693,DB02701,Nicotinamide
,27909950,response rates,"Disease control and response rates (partial responses only) were 48 and 6.6%, respectively.","HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),%,6.6,69694,DB02701,Nicotinamide
,27909950,TTP,Median TTP from Child-Pugh A to B/C was 88 days.,"HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27909950/),d,88,69695,DB02701,Nicotinamide
,23275061,dissociation constant (Ki),"LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min.","LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23275061/),nM,2,71840,DB02701,Nicotinamide
,23275061,dynamic residence time (Koff),"LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min.","LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23275061/),1/[min],0.00132,71841,DB02701,Nicotinamide
,23275061,t1/2,"LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min.","LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23275061/),min,525,71842,DB02701,Nicotinamide
,16006586,MTD,The MTD was 400 mg twice daily.,"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006586/),mg,400,73964,DB02701,Nicotinamide
,16006586,duration of stable disease,Stable disease was achieved in 22% of patients; median duration of stable disease was 7.2 months.,"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006586/),month,7.2,73965,DB02701,Nicotinamide
,16006586,half-life,"Consistent with its observed half-life of approximately 27 h, BAY 43-9, 006 accumulated on multiple dosing.","Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006586/),h,27,73966,DB02701,Nicotinamide
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,12,76857,DB02701,Nicotinamide
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,26,76858,DB02701,Nicotinamide
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,15,76859,DB02701,Nicotinamide
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,10,76860,DB02701,Nicotinamide
,25294187,overall response rate,"The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,0,76861,DB02701,Nicotinamide
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,58,76862,DB02701,Nicotinamide
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,90,76863,DB02701,Nicotinamide
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,65,76864,DB02701,Nicotinamide
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,63,76865,DB02701,Nicotinamide
,25294187,Disease control rate,"Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294187/),%,40,76866,DB02701,Nicotinamide
,17951335,progression-free survival,Median progression-free survival was 224 days and the 25th percentile of overall survival was estimated at 288 days.,"Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951335/),d,224,78570,DB02701,Nicotinamide
,17951335,overall survival,Median progression-free survival was 224 days and the 25th percentile of overall survival was estimated at 288 days.,"Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951335/),d,288,78571,DB02701,Nicotinamide
,12585088,disintegration time,"The disintegration time of FD tablets containing 1% croscarmellose sodium with 6 mm and 10 mm in diameter were about 12 and 23 seconds, respectively.",[Pharmaceutical evaluation of fast-disintegrant tablet containing nicorandil-loaded particles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12585088/),seconds,12,79602,DB02701,Nicotinamide
,12585088,disintegration time,"The disintegration time of FD tablets containing 1% croscarmellose sodium with 6 mm and 10 mm in diameter were about 12 and 23 seconds, respectively.",[Pharmaceutical evaluation of fast-disintegrant tablet containing nicorandil-loaded particles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12585088/),seconds,23,79603,DB02701,Nicotinamide
,3006735,enhancement ratio (ER),"When given at this time, the nicotinamide had a dose-modifying effect on all L-PAM doses tested, giving rise to a mean enhancement ratio (ER) of 2.2.",Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006735/),,2.2,79627,DB02701,Nicotinamide
,3006735,half-life,"In addition the inhibitor also delayed the clearance of L-PAM from the plasma of C3H mice, such that the half-life of the chemotherapeutic agent was extended from 41 min to 143 min.",Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006735/),min,41,79628,DB02701,Nicotinamide
,3006735,half-life,"In addition the inhibitor also delayed the clearance of L-PAM from the plasma of C3H mice, such that the half-life of the chemotherapeutic agent was extended from 41 min to 143 min.",Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006735/),min,143,79629,DB02701,Nicotinamide
,27935260,CLH,"The predicted CLH of flubromazolam using the well-stirred and parallel-tube models were 0.42 and 0.43 mL/min/kg, respectively.",In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935260/),[ml] / [kg·min],0.42,79959,DB02701,Nicotinamide
,27935260,CLH,"The predicted CLH of flubromazolam using the well-stirred and parallel-tube models were 0.42 and 0.43 mL/min/kg, respectively.",In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935260/),[ml] / [kg·min],0.43,79960,DB02701,Nicotinamide
,24060438,liver-to-serum ratios,The average liver-to-serum ratios 24 hours and 72 hours after treatment were approximately 14 and 22.,Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060438/),,14,80160,DB02701,Nicotinamide
,24060438,liver-to-serum ratios,The average liver-to-serum ratios 24 hours and 72 hours after treatment were approximately 14 and 22.,Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060438/),,22,80161,DB02701,Nicotinamide
,20853461,flow rate,"The chromatographic separation of NA, NAM, NUA, 2-Pyr and IS was achieved on a Hypersil-BDS column (150 x 4.6 mm, 5 microm) column using a mobile phase consisting of 0.1% formic acid : acetonitrile (20:80 v/v) at a flow rate of 1 mL/min.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),[ml] / [min],1,80509,DB02701,Nicotinamide
,20853461,total run time of analysis,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,2,80510,DB02701,Nicotinamide
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.37,80511,DB02701,Nicotinamide
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.46,80512,DB02701,Nicotinamide
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.40,80513,DB02701,Nicotinamide
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.06,80514,DB02701,Nicotinamide
,20853461,elution,"The total run time of analysis was 2 min and elution of NA, NAM, NUA, 2-Pyr and IS occurred at 1.37, 1.46, 1.40, 1.06 and 1.27 min, respectively.","Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853461/),min,1.27,80515,DB02701,Nicotinamide
,8260362,half-life,The half-life of nicotinamide increased from 1.4 h to 2.2 h over the dose range (P < 0.01).,Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260362/),h,1.4,82347,DB02701,Nicotinamide
,8260362,half-life,The half-life of nicotinamide increased from 1.4 h to 2.2 h over the dose range (P < 0.01).,Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260362/),h,2.2,82348,DB02701,Nicotinamide
,8260362,surviving fraction,"At a surviving fraction of 0.02, enhancement ratios of 1.39-1.48 were obtained for carbogen plus 0.1 to 0.3 mg g-1 of nicotinamide.",Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260362/),,0.02,82349,DB02701,Nicotinamide
,8260362,enhancement ratios,"At a surviving fraction of 0.02, enhancement ratios of 1.39-1.48 were obtained for carbogen plus 0.1 to 0.3 mg g-1 of nicotinamide.",Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260362/),,0.02,82350,DB02701,Nicotinamide
,8260362,enhancement ratios,"At a surviving fraction of 0.02, enhancement ratios of 1.39-1.48 were obtained for carbogen plus 0.1 to 0.3 mg g-1 of nicotinamide.",Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260362/),,1.39-1.48,82351,DB02701,Nicotinamide
,8260362,ERs,These were lower than those seen with the two higher doses of 0.4 to 0.5 mg g-1 (ERs = 1.63-1.69).,Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8260362/),,1.63-1.69,82352,DB02701,Nicotinamide
,19569735,clearance,This compound showed high in vivo clearance in rats (160 ml min(-1) kg(-1)) due to metabolism.,Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569735/),[ml] / [kg·min],160,86130,DB02701,Nicotinamide
,17095207,K(i),"In vitro, sorafenib strongly inhibited SN38 glucuronidation in human liver microsomes as indicated by a K(i) value of 2.7 micromol/l.",Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17095207/),[μM] / [l],2.7,89198,DB02701,Nicotinamide
,31758056,zeta potential,"SGNCF1 showed spherical shape, small particle size (106.3 ± 2.69 nm), good zeta potential (-18.2 ± 1.30 mV), small PDI (0.222 ± 0.104) and high entrapment efficiency (86.27 ± 0.222%).",Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758056/),m,-,90065,DB02701,Nicotinamide
,31758056,zeta potential,"SGNCF1 showed spherical shape, small particle size (106.3 ± 2.69 nm), good zeta potential (-18.2 ± 1.30 mV), small PDI (0.222 ± 0.104) and high entrapment efficiency (86.27 ± 0.222%).",Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758056/),m,18.2,90066,DB02701,Nicotinamide
,31758056,entrapment efficiency,"SGNCF1 showed spherical shape, small particle size (106.3 ± 2.69 nm), good zeta potential (-18.2 ± 1.30 mV), small PDI (0.222 ± 0.104) and high entrapment efficiency (86.27 ± 0.222%).",Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758056/),%,86.27,90067,DB02701,Nicotinamide
,20073472,maximum concentrations,"Trigonelline plasma levels increased from 160 nmol/L to maximum concentrations of 5479 (males) or 6547 nmol/L (females), and N-methylpyridinium plasma levels raised from virtually complete absence to maximum values of 777 (females) or 804 nmol/L (males) within 2-3 and 1-2 h after coffee consumption, respectively.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),[nM] / [l],5479,91138,DB02701,Nicotinamide
,20073472,maximum concentrations,"Trigonelline plasma levels increased from 160 nmol/L to maximum concentrations of 5479 (males) or 6547 nmol/L (females), and N-methylpyridinium plasma levels raised from virtually complete absence to maximum values of 777 (females) or 804 nmol/L (males) within 2-3 and 1-2 h after coffee consumption, respectively.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),[nM] / [l],6547,91139,DB02701,Nicotinamide
,20073472,maximum values,"Trigonelline plasma levels increased from 160 nmol/L to maximum concentrations of 5479 (males) or 6547 nmol/L (females), and N-methylpyridinium plasma levels raised from virtually complete absence to maximum values of 777 (females) or 804 nmol/L (males) within 2-3 and 1-2 h after coffee consumption, respectively.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),[nM] / [l],777,91140,DB02701,Nicotinamide
,20073472,maximum values,"Trigonelline plasma levels increased from 160 nmol/L to maximum concentrations of 5479 (males) or 6547 nmol/L (females), and N-methylpyridinium plasma levels raised from virtually complete absence to maximum values of 777 (females) or 804 nmol/L (males) within 2-3 and 1-2 h after coffee consumption, respectively.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),[nM] / [l],804,91141,DB02701,Nicotinamide
,20073472,urinary excretion,"Within 8 h after coffee intervention, an urinary excretion of 57.4 +/- 6.9% of trigonelline and 69.1 +/- 6.2% of N-methylpyridinium was found for the male volunteers, whereas females excreted slightly less with 46.2 +/- 7.4% and 61.9 +/- 12.2% of these pyridines.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),%,57.4,91142,DB02701,Nicotinamide
,20073472,urinary excretion,"Within 8 h after coffee intervention, an urinary excretion of 57.4 +/- 6.9% of trigonelline and 69.1 +/- 6.2% of N-methylpyridinium was found for the male volunteers, whereas females excreted slightly less with 46.2 +/- 7.4% and 61.9 +/- 12.2% of these pyridines.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),%,69.1,91143,DB02701,Nicotinamide
,20073472,urinary excretion,"Within 8 h after coffee intervention, an urinary excretion of 57.4 +/- 6.9% of trigonelline and 69.1 +/- 6.2% of N-methylpyridinium was found for the male volunteers, whereas females excreted slightly less with 46.2 +/- 7.4% and 61.9 +/- 12.2% of these pyridines.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),%,46.2,91144,DB02701,Nicotinamide
,20073472,urinary excretion,"Within 8 h after coffee intervention, an urinary excretion of 57.4 +/- 6.9% of trigonelline and 69.1 +/- 6.2% of N-methylpyridinium was found for the male volunteers, whereas females excreted slightly less with 46.2 +/- 7.4% and 61.9 +/- 12.2% of these pyridines.",Development of a hydrophilic liquid interaction chromatography-high-performance liquid chromatography-tandem mass spectrometry based stable isotope dilution analysis and pharmacokinetic studies on bioactive pyridines in human plasma and urine after coffee consumption. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20073472/),%,61.9,91145,DB02701,Nicotinamide
,12142092,maximum plasma nicotinamide concentration,The mean maximum plasma nicotinamide concentration was 793 nmol/ml without domperidone and 776 nmol/ml with domperidone.,Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142092/),[nM] / [ml],793,91329,DB02701,Nicotinamide
,12142092,maximum plasma nicotinamide concentration,The mean maximum plasma nicotinamide concentration was 793 nmol/ml without domperidone and 776 nmol/ml with domperidone.,Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142092/),[nM] / [ml],776,91330,DB02701,Nicotinamide
,12142092,time at which the maximum concentration occurred,The median time at which the maximum concentration occurred was not significantly different for 60 mg/kg nicotinamide without or with domperidone (0.46 versus 0.54 h).,Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142092/),h,0.46,91331,DB02701,Nicotinamide
,12142092,time at which the maximum concentration occurred,The median time at which the maximum concentration occurred was not significantly different for 60 mg/kg nicotinamide without or with domperidone (0.46 versus 0.54 h).,Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142092/),h,0.54,91332,DB02701,Nicotinamide
>,32201308,apparent solubility,CAGE provided excellent apparent solubility of SRF tosylate (> 500 mg/mL).,Oral delivery of sorafenib through spontaneous formation of ionic liquid nanocomplexes. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32201308/),[mg] / [ml],500,91871,DB02701,Nicotinamide
,27207170,Kd,"From three test/retest studies, [11C]GSK189254 Kd was estimated to be 9.5 ± 5.9 pM.",Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207170/),pM,9.5,93884,DB02701,Nicotinamide
,27207170,occupancy,"Oral administration of 0.1 to 4 mg of PF-03654746 resulted in occupancy estimates of 71%-97% and 30%-93% at 3 and 24 h post-drug, respectively.",Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207170/),%,71,93885,DB02701,Nicotinamide
,27207170,occupancy,"Oral administration of 0.1 to 4 mg of PF-03654746 resulted in occupancy estimates of 71%-97% and 30%-93% at 3 and 24 h post-drug, respectively.",Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207170/),%,97,93886,DB02701,Nicotinamide
,27207170,occupancy,"Oral administration of 0.1 to 4 mg of PF-03654746 resulted in occupancy estimates of 71%-97% and 30%-93% at 3 and 24 h post-drug, respectively.",Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207170/),%,30,93887,DB02701,Nicotinamide
,27207170,occupancy,"Oral administration of 0.1 to 4 mg of PF-03654746 resulted in occupancy estimates of 71%-97% and 30%-93% at 3 and 24 h post-drug, respectively.",Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207170/),%,93,93888,DB02701,Nicotinamide
,27207170,IC50,"Analysis of the relationship between corrected occupancies and PF-03654746 plasma levels indicated that PF-03654746 can fully occupy H3 binding sites ( ROmax = 100%), and its IC50 was estimated to be 0.144 ± 0.010 ng/mL.",Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207170/),[ng] / [ml],0.144,93889,DB02701,Nicotinamide
,24365980,constant flow rate,"After protein precipitation with acetonitrile, sorafenib and lapatinib (internal standard) were separated using isocratic elution on a Kromasil C18 column using a mobile phase of acetonitrile and 20 mmol/L ammonium acetate in a proportion 53:47 (vol/vol) pumped at a constant flow rate of 1.2 mL/min.",Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365980/),[ml] / [min],1.2,97302,DB02701,Nicotinamide
>,24365980,Recoveries,Recoveries of sorafenib from plasma were >99% in all cases.,Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365980/),%,99,97303,DB02701,Nicotinamide
,18782142,E(max),An inhibitory E(max) model with E(max) of -11.7 mmHg and EC(50) of 423 microg l(-1) was considered the best relationship between nicorandil concentrations and PAWP.,Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18782142/),mmhg,-,97548,DB02701,Nicotinamide
,18782142,E(max),An inhibitory E(max) model with E(max) of -11.7 mmHg and EC(50) of 423 microg l(-1) was considered the best relationship between nicorandil concentrations and PAWP.,Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18782142/),mmhg,11.7,97549,DB02701,Nicotinamide
,18782142,EC(50),An inhibitory E(max) model with E(max) of -11.7 mmHg and EC(50) of 423 microg l(-1) was considered the best relationship between nicorandil concentrations and PAWP.,Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18782142/),[μg] / [l],423,97550,DB02701,Nicotinamide
,18782142,half-life,This drug independent decline was described by an asymptotic decrease of 6.1 mmHg with a half-life of 5.3 h.,Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18782142/),h,5.3,97551,DB02701,Nicotinamide
,23099651,PFS,Median PFS was 8 weeks.,Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099651/),,8,102403,DB02701,Nicotinamide
,26644411,plasma half-life,"Refametinib was readily absorbed following oral administration (plasma half-life of ∼16 hours at the MTD), and pharmacokinetic parameters displayed near-dose proportionality, with less than 2-fold accumulation after multiple dosing.","A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26644411/),h,∼16,107025,DB02701,Nicotinamide
,30257601,Plasma clearance,"Plasma clearance was low in monkeys and dogs (9.14 mL min-1 kg-1 and 4.62 mL min-1 kg-1, respectively) and moderate in mice and rats (36.4 mL min-1 kg-1 and 19.3 mL min-1 kg-1, respectively).","Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),[ml] / [kg·min],9.14,108322,DB02701,Nicotinamide
,30257601,Plasma clearance,"Plasma clearance was low in monkeys and dogs (9.14 mL min-1 kg-1 and 4.62 mL min-1 kg-1, respectively) and moderate in mice and rats (36.4 mL min-1 kg-1 and 19.3 mL min-1 kg-1, respectively).","Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),[ml] / [kg·min],4.62,108323,DB02701,Nicotinamide
,30257601,Plasma clearance,"Plasma clearance was low in monkeys and dogs (9.14 mL min-1 kg-1 and 4.62 mL min-1 kg-1, respectively) and moderate in mice and rats (36.4 mL min-1 kg-1 and 19.3 mL min-1 kg-1, respectively).","Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),[ml] / [kg·min],36.4,108324,DB02701,Nicotinamide
,30257601,Plasma clearance,"Plasma clearance was low in monkeys and dogs (9.14 mL min-1 kg-1 and 4.62 mL min-1 kg-1, respectively) and moderate in mice and rats (36.4 mL min-1 kg-1 and 19.3 mL min-1 kg-1, respectively).","Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),[ml] / [kg·min],19.3,108325,DB02701,Nicotinamide
,30257601,Oral bioavailability,"Oral bioavailability in mice, rats, monkeys and dogs was 29.7, 33.9, 29.4 and 65.2%, respectively.","Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),%,29.7,108326,DB02701,Nicotinamide
,30257601,Oral bioavailability,"Oral bioavailability in mice, rats, monkeys and dogs was 29.7, 33.9, 29.4 and 65.2%, respectively.","Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),%,33.9,108327,DB02701,Nicotinamide
,30257601,Oral bioavailability,"Oral bioavailability in mice, rats, monkeys and dogs was 29.7, 33.9, 29.4 and 65.2%, respectively.","Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),%,29.4,108328,DB02701,Nicotinamide
,30257601,Oral bioavailability,"Oral bioavailability in mice, rats, monkeys and dogs was 29.7, 33.9, 29.4 and 65.2%, respectively.","Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),%,65.2,108329,DB02701,Nicotinamide
,30257601,clearance,Allometric scaling predicted a low clearance of 3.3 mL min-1 kg-1 and a volume of distribution of 1.3 L kg-1 in human.,"Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),[ml] / [kg·min],3.3,108330,DB02701,Nicotinamide
,30257601,volume of distribution,Allometric scaling predicted a low clearance of 3.3 mL min-1 kg-1 and a volume of distribution of 1.3 L kg-1 in human.,"Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),[l] / [kg],1.3,108331,DB02701,Nicotinamide
,30257601,AUC,Efficacy (57% tumor growth inhibition) in Colo-205 CRC tumor xenograft mice was observed at an oral dose of 15 mg/kg BID (AUC = 10.4 µM h).,"Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257601/),h·μM,10.4,108332,DB02701,Nicotinamide
,26117830,progression-free survival,The median progression-free survival was 9.9 (95% CI 6.5-17.1) months.,Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26117830/),month,9.9,109490,DB02701,Nicotinamide
,32366155,trough concentration,"Patients had a median trough concentration of 3217 ng/ml (IQR 2166-4526) and 360 ng/ml (IQR 190-593) with coefficients of variation of 65% and 146% for sorafenib and M2, respectively.",The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32366155/),[ng] / [ml],3217,111821,DB02701,Nicotinamide
,32366155,trough concentration,"Patients had a median trough concentration of 3217 ng/ml (IQR 2166-4526) and 360 ng/ml (IQR 190-593) with coefficients of variation of 65% and 146% for sorafenib and M2, respectively.",The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32366155/),[ng] / [ml],360,111822,DB02701,Nicotinamide
,32366155,trough levels,"Patients who experienced severe sorafenib-related toxicity received a lower average daily dose (551 vs 730 mg/day, p = .003), but showed no significant differences in sorafenib (3298 vs 2915 ng/ml, p = .442) or M2 trough levels (428 vs 283 ng/ml, p = .159).",The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32366155/),[ng] / [ml],428,111823,DB02701,Nicotinamide
,32366155,trough levels,"Patients who experienced severe sorafenib-related toxicity received a lower average daily dose (551 vs 730 mg/day, p = .003), but showed no significant differences in sorafenib (3298 vs 2915 ng/ml, p = .442) or M2 trough levels (428 vs 283 ng/ml, p = .159).",The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32366155/),[ng] / [ml],283,111824,DB02701,Nicotinamide
,17557949,MTD,The MTD was 125 mg once daily administered continuously.,"Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17557949/),mg,125,117641,DB02701,Nicotinamide
,22738637,EC(50),ML293 exhibited modest potency at the human M4 receptor (EC(50)=1.3 μM) and excellent efficacy as noted by the 14.6-fold leftward shift of the agonist concentration-response curve.,"Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738637/),μM,1.3,117826,DB02701,Nicotinamide
,22738637,IV clearance,"ML293 was also selective versus the other muscarinic subtypes and displayed excellent in vivo PK properties in rat with low IV clearance (11.6 mL/min/kg) and excellent brain exposure (PO PBL, 10 mg/kg at 1h, [Brain]=10.3 μM, B:P=0.85).","Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738637/),[ml] / [kg·min],11.6,117827,DB02701,Nicotinamide
,22738637,Brain],"ML293 was also selective versus the other muscarinic subtypes and displayed excellent in vivo PK properties in rat with low IV clearance (11.6 mL/min/kg) and excellent brain exposure (PO PBL, 10 mg/kg at 1h, [Brain]=10.3 μM, B:P=0.85).","Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738637/),,10.3,117828,DB02701,Nicotinamide
,24132922,MTD,The MTD of sorafenib was 400 mg daily.,Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24132922/),mg,400,118739,DB02701,Nicotinamide
,6233416,t1/2,"The pharmacokinetic data derived from intravenous administration of nicorandil were: t1/2, 0.73 plus/minus 0.11 h; Vdarea , 0.67 plus/minus 0.04 L/kg; and total plasma clearance, 13.50 plus/minus 1.05 mL/min/kg.","Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6233416/),h,0.73,119930,DB02701,Nicotinamide
,6233416,Vdarea,"The pharmacokinetic data derived from intravenous administration of nicorandil were: t1/2, 0.73 plus/minus 0.11 h; Vdarea , 0.67 plus/minus 0.04 L/kg; and total plasma clearance, 13.50 plus/minus 1.05 mL/min/kg.","Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6233416/),[l] / [kg],0.67,119931,DB02701,Nicotinamide
,6233416,total plasma clearance,"The pharmacokinetic data derived from intravenous administration of nicorandil were: t1/2, 0.73 plus/minus 0.11 h; Vdarea , 0.67 plus/minus 0.04 L/kg; and total plasma clearance, 13.50 plus/minus 1.05 mL/min/kg.","Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6233416/),[ml] / [kg·min],13.50,119932,DB02701,Nicotinamide
,6233416,tmax,"After oral administration, nicorandil was rapidly absorbed (tmax, 0.58 plus/minus 0.11 h).","Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6233416/),h,0.58,119933,DB02701,Nicotinamide
,6233416,oral bioavailability,The oral bioavailability was calculated as 0.72 plus/minus 0.07.,"Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6233416/),,0.72,119934,DB02701,Nicotinamide
,6233416,elimination half-life,"The metabolic formation of the corresponding alcohol after intravenous and oral administration of the parent compound appeared to occur quite efficiently, and its elimination half-life (3.09 plus/minus 0.25 and 3.69 plus/minus 0.88 h after intravenous and oral administration of nicorandil, respectively) was longer than that of the parent compound.","Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6233416/),h,3.09,119935,DB02701,Nicotinamide
,6233416,elimination half-life,"The metabolic formation of the corresponding alcohol after intravenous and oral administration of the parent compound appeared to occur quite efficiently, and its elimination half-life (3.09 plus/minus 0.25 and 3.69 plus/minus 0.88 h after intravenous and oral administration of nicorandil, respectively) was longer than that of the parent compound.","Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6233416/),h,3.69,119936,DB02701,Nicotinamide
,20406832,Progression-free survival,Progression-free survival ranged from 7.9 to 121.9 weeks.,A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406832/),weeks,7.9 to 121.9,121262,DB02701,Nicotinamide
,8356223,peak plasma concentration,The average peak plasma concentration of 160 micrograms/ml measured in humans after taking 6 g of nicotinamide was equivalent to that seen in mice after injecting 171 mg/kg.,Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8356223/),[μg] / [ml],160,121889,DB02701,Nicotinamide
,239599,tubularmaximum (Tm),"Renal clearance experiments clearly demonstrated that: 1) NMN is secreted; 2)a tubularmaximum (Tm), 7 mumol/min per kg, could be reached; and 3)NMN secretion is inhibitedby a competitive inhibitor, mepiperphenidol.",Renal excretion of N'1-methylnicotinamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/239599/),[μM] / [kg·min],7,122558,DB02701,Nicotinamide
,239599,inblin ratio,"In free-flow micropuncture experiments, animals were infused with plasma concentrations of NMN ABOVE Tm; the TF/P NMNto TF/P inblin ratio for proximal and distal samples was 2.34 and 2.28, respectively, indicating that NMN is secreted in the proximal tubules and is not secreted orreabsorbed in the distal tubules.",Renal excretion of N'1-methylnicotinamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/239599/),,2.34,122559,DB02701,Nicotinamide
,239599,inblin ratio,"In free-flow micropuncture experiments, animals were infused with plasma concentrations of NMN ABOVE Tm; the TF/P NMNto TF/P inblin ratio for proximal and distal samples was 2.34 and 2.28, respectively, indicating that NMN is secreted in the proximal tubules and is not secreted orreabsorbed in the distal tubules.",Renal excretion of N'1-methylnicotinamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/239599/),,2.28,122560,DB02701,Nicotinamide
,7976386,blood Nik levels,The blood Nik levels were 7.9 and 10.6 micrograms.,[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),μg,7.9,124766,DB02701,Nicotinamide
,7976386,blood Nik levels,The blood Nik levels were 7.9 and 10.6 micrograms.,[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),μg,10.6,124767,DB02701,Nicotinamide
,7976386,maxima,ml-1 at 0.5 min and reached the maxima of 12.8 and 31.9 micrograms.,[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),μg,12.8,124768,DB02701,Nicotinamide
,7976386,maxima,ml-1 at 0.5 min and reached the maxima of 12.8 and 31.9 micrograms.,[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),μg,31.9,124769,DB02701,Nicotinamide
,7976386,T1/2Ka,"kg-1 were fitted to a 2-compartment open model with T1/2Ka 0.48 and 0.85 min, T1/2 alpha 2.37 and 1.68 min, T 1/2 beta 114 and 130 min, AUC 1201 and 2790 micrograms.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),min,0.48,124770,DB02701,Nicotinamide
,7976386,T1/2Ka,"kg-1 were fitted to a 2-compartment open model with T1/2Ka 0.48 and 0.85 min, T1/2 alpha 2.37 and 1.68 min, T 1/2 beta 114 and 130 min, AUC 1201 and 2790 micrograms.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),min,0.85,124771,DB02701,Nicotinamide
,7976386,T1/2 alpha,"kg-1 were fitted to a 2-compartment open model with T1/2Ka 0.48 and 0.85 min, T1/2 alpha 2.37 and 1.68 min, T 1/2 beta 114 and 130 min, AUC 1201 and 2790 micrograms.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),min,2.37,124772,DB02701,Nicotinamide
,7976386,T1/2 alpha,"kg-1 were fitted to a 2-compartment open model with T1/2Ka 0.48 and 0.85 min, T1/2 alpha 2.37 and 1.68 min, T 1/2 beta 114 and 130 min, AUC 1201 and 2790 micrograms.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),min,1.68,124773,DB02701,Nicotinamide
,7976386,T 1/2 beta,"kg-1 were fitted to a 2-compartment open model with T1/2Ka 0.48 and 0.85 min, T1/2 alpha 2.37 and 1.68 min, T 1/2 beta 114 and 130 min, AUC 1201 and 2790 micrograms.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),min,114,124774,DB02701,Nicotinamide
,7976386,T 1/2 beta,"kg-1 were fitted to a 2-compartment open model with T1/2Ka 0.48 and 0.85 min, T1/2 alpha 2.37 and 1.68 min, T 1/2 beta 114 and 130 min, AUC 1201 and 2790 micrograms.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),min,130,124775,DB02701,Nicotinamide
,7976386,AUC,"kg-1 were fitted to a 2-compartment open model with T1/2Ka 0.48 and 0.85 min, T1/2 alpha 2.37 and 1.68 min, T 1/2 beta 114 and 130 min, AUC 1201 and 2790 micrograms.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),μg,1201,124776,DB02701,Nicotinamide
,7976386,AUC,"kg-1 were fitted to a 2-compartment open model with T1/2Ka 0.48 and 0.85 min, T1/2 alpha 2.37 and 1.68 min, T 1/2 beta 114 and 130 min, AUC 1201 and 2790 micrograms.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),μg,2790,124777,DB02701,Nicotinamide
,7976386,bioavailability,"ml-1, bioavailability 84.7% and 65.5%, respectively.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),%,84.7,124778,DB02701,Nicotinamide
,7976386,bioavailability,"ml-1, bioavailability 84.7% and 65.5%, respectively.",[Pharmacokinetics and pharmacodynamics of nikethamide after endotracheal administration in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7976386/),%,65.5,124779,DB02701,Nicotinamide
,21768474,binding constant,"In vitro, the N-oxide potently inhibited FLT3-internal tandem duplication (ITD; binding constant, 70 nmol/L) and the viability of five AML cell lines.",Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21768474/),[nM] / [l],70,125556,DB02701,Nicotinamide
,23143218,apparent oral clearance,Median day 1 cyclophosphamide apparent oral clearance was 3.13 L/h/m(2).,"Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143218/),[h·l] / [m(2],3.13,126459,DB02701,Nicotinamide
,23143218,apparent oral clearance,"Median day 1 sorafenib apparent oral clearance was 44 and 39 mL/min/m(2) at the 2 dose levels evaluated, and steady-state concentrations ranged from 1.64 to 4.8 mg/L.","Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143218/),[min·ml] / [m(2],44,126460,DB02701,Nicotinamide
,23143218,apparent oral clearance,"Median day 1 sorafenib apparent oral clearance was 44 and 39 mL/min/m(2) at the 2 dose levels evaluated, and steady-state concentrations ranged from 1.64 to 4.8 mg/L.","Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143218/),[min·ml] / [m(2],39,126461,DB02701,Nicotinamide
,23143218,steady-state concentrations,"Median day 1 sorafenib apparent oral clearance was 44 and 39 mL/min/m(2) at the 2 dose levels evaluated, and steady-state concentrations ranged from 1.64 to 4.8 mg/L.","Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143218/),[mg] / [l],1.64 to 4.8,126462,DB02701,Nicotinamide
,7921519,Renal blood flow,Renal blood flow averaged 655 +/- 28 ml/minute/1.73 m2 after placebo.,Acute effects of increasing doses of nicorandil on renal function in man. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7921519/),[ml] / [1.73·m2·min],655,126463,DB02701,Nicotinamide
,27307733,polydispersity index,"Sorafenib-LNS were prepared by nanoprecipitation and consisted of spherical particles with a uniform size distribution (164.5 nm, polydispersity index =0.202) and negative zeta potential (-11.0 mV).","In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27307733/),,0.202,127196,DB02701,Nicotinamide
,27307733,drug loading (DL),The drug loading (DL) was 10.55%±0.16%.,"In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27307733/),%,10.55,127197,DB02701,Nicotinamide
,21954442,MTD,The MTD was 600 mg BID for patients receiving EIASDs and 800 mg BID for those who were not.,Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21954442/),mg,600,127386,DB02701,Nicotinamide
,23146956,disease control rate,The disease control rate overall was 63%.,Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146956/),%,63,129196,DB02701,Nicotinamide
,20872147,objective response rate,"The predicted objective response rate and median progression-free survival in patients with differentiated thyroid cancer was 15.0% (95% prediction interval, 7.5%-23.7%) and 40 weeks (95% prediction interval, 32-49 weeks), respectively, compared with the observed objective response rate of 14.0% and median progression-free survival of 40 weeks.",Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872147/),%,15.0,129435,DB02701,Nicotinamide
,20872147,progression-free survival,"The predicted objective response rate and median progression-free survival in patients with differentiated thyroid cancer was 15.0% (95% prediction interval, 7.5%-23.7%) and 40 weeks (95% prediction interval, 32-49 weeks), respectively, compared with the observed objective response rate of 14.0% and median progression-free survival of 40 weeks.",Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872147/),weeks,40,129436,DB02701,Nicotinamide
,20872147,objective response rate,"The predicted objective response rate and median progression-free survival in patients with differentiated thyroid cancer was 15.0% (95% prediction interval, 7.5%-23.7%) and 40 weeks (95% prediction interval, 32-49 weeks), respectively, compared with the observed objective response rate of 14.0% and median progression-free survival of 40 weeks.",Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872147/),%,14.0,129437,DB02701,Nicotinamide
,20872147,progression-free survival,"The predicted objective response rate and median progression-free survival in patients with differentiated thyroid cancer was 15.0% (95% prediction interval, 7.5%-23.7%) and 40 weeks (95% prediction interval, 32-49 weeks), respectively, compared with the observed objective response rate of 14.0% and median progression-free survival of 40 weeks.",Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872147/),weeks,40,129438,DB02701,Nicotinamide
,20872147,progression-free survival,"However, simulated median progression-free survival was independent of starting dose, ranging from 40.5 weeks (95% prediction interval, 38.6-46.9 weeks) at 100 mg once daily to 40.0 weeks (95% prediction interval, 38.6-46.8 weeks) at 250 mg once daily.",Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872147/),weeks,40.5,129439,DB02701,Nicotinamide
,20872147,progression-free survival,"However, simulated median progression-free survival was independent of starting dose, ranging from 40.5 weeks (95% prediction interval, 38.6-46.9 weeks) at 100 mg once daily to 40.0 weeks (95% prediction interval, 38.6-46.8 weeks) at 250 mg once daily.",Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872147/),weeks,40.0,129440,DB02701,Nicotinamide
,19760364,area under the curve [AUC],"Eligible patients received paclitaxel (200 mg/m(2)) and carboplatin (area under the curve [AUC]of 6 mg min mL(-1)) on day 1 and sorafenib (400 mg, twice daily) on days 2 through 19 of a 21-day cycle.",Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19760364/),[mg·min] / [ml],6,129762,DB02701,Nicotinamide
,19760364,AUC,The present study confirmed that sorafenib at 400 mg once daily in combination with carboplatin AUC 5 mg min mL(-1) and paclitaxel 200 mg/m(2) is feasible in Japanese patients with advanced NSCLC.,Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19760364/),[mg·min] / [ml],5,129763,DB02701,Nicotinamide
,16908937,time to progression (TTP),"Investigator-assessed median time to progression (TTP) was 4.2 months, and median overall survival was 9.2 months.",Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16908937/),month,4.2,136066,DB02701,Nicotinamide
,16908937,overall survival,"Investigator-assessed median time to progression (TTP) was 4.2 months, and median overall survival was 9.2 months.",Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16908937/),month,9.2,136067,DB02701,Nicotinamide
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],2.09,136631,DB02701,Nicotinamide
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],1.78,136632,DB02701,Nicotinamide
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],68.1,136633,DB02701,Nicotinamide
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],64.3,136634,DB02701,Nicotinamide
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.00,136635,DB02701,Nicotinamide
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.02,136636,DB02701,Nicotinamide
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,24.0,136637,DB02701,Nicotinamide
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,25.7,136638,DB02701,Nicotinamide
,32905447,half-life,"In vitro, PA's half-life is 21.4 min and 48.1 min in mouse and human liver microsomes, respectively.",Pharmacokinetics of Panaxynol in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905447/),min,21.4,139816,DB02701,Nicotinamide
,32905447,half-life,"In vitro, PA's half-life is 21.4 min and 48.1 min in mouse and human liver microsomes, respectively.",Pharmacokinetics of Panaxynol in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905447/),min,48.1,139817,DB02701,Nicotinamide
,32905447,half-life,"In vivo, PA has a half-life of 1.5 hr when IV-injected, and 5.9 hr when administered via PO, with a moderate bioavailability of 50.4%.",Pharmacokinetics of Panaxynol in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905447/),h,1.5,139818,DB02701,Nicotinamide
,32905447,half-life,"In vivo, PA has a half-life of 1.5 hr when IV-injected, and 5.9 hr when administered via PO, with a moderate bioavailability of 50.4%.",Pharmacokinetics of Panaxynol in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905447/),h,5.9,139819,DB02701,Nicotinamide
,32905447,bioavailability,"In vivo, PA has a half-life of 1.5 hr when IV-injected, and 5.9 hr when administered via PO, with a moderate bioavailability of 50.4%.",Pharmacokinetics of Panaxynol in Mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32905447/),%,50.4,139820,DB02701,Nicotinamide
,20554726,oral dose equaling 50% occupancy,The oral dose equaling 50% occupancy of the available receptor sites (ED(50)) was estimated as 4.33 microg.,Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20554726/),μg,4.33,140951,DB02701,Nicotinamide
,20554726,EC(50)),Additional data on plasma pharmacokinetics after oral dosing and the plasma free fraction gave a corresponding estimate of the free concentration of GSK189254 required to occupy 50% of the available receptor sites (EC(50)) (0.011 nM).,Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20554726/),nM,0.011,140952,DB02701,Nicotinamide
,20554726,apparent dissociation constant,"A nonlinear compartmental analysis of this effect demonstrated that this reduction was consistent with carryover of a tracer mass dose effect with an estimated in vivo apparent dissociation constant of 0.010 nM, close to the independent estimate of the plasma EC(50).",Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20554726/),nM,0.010,140953,DB02701,Nicotinamide
,19154507,progression-free survival,"At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months.",Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19154507/),month,3.7,141835,DB02701,Nicotinamide
,19154507,overall survival,"At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months.",Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19154507/),month,18.0,141836,DB02701,Nicotinamide
,19154507,survival,For the whole trial of 46 patients the median survival was 18.3 months.,Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19154507/),month,18,141837,DB02701,Nicotinamide
,22038662,AUC,"Sorafenib AUC significantly decreased over time: the median AUC during the third month of treatment was lower than that observed after one month of treatment (43.0 vs. 60.3 mg/L.h, p = 0.008).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [h·l],43.0,143283,DB02701,Nicotinamide
,22038662,AUC,"Sorafenib AUC significantly decreased over time: the median AUC during the third month of treatment was lower than that observed after one month of treatment (43.0 vs. 60.3 mg/L.h, p = 0.008).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [h·l],60.3,143284,DB02701,Nicotinamide
,22038662,AUC,"Most importantly, median sorafenib AUC at the time of progression was almost two-fold lower than that observed after one month of therapy (33.2 vs. 60.3 mg/L.h, p = 0.007).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [h·l],33.2,143285,DB02701,Nicotinamide
,22038662,AUC,"Most importantly, median sorafenib AUC at the time of progression was almost two-fold lower than that observed after one month of therapy (33.2 vs. 60.3 mg/L.h, p = 0.007).",Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22038662/),[mg] / [h·l],60.3,143286,DB02701,Nicotinamide
,23739952,portal clearance,"The mean (±S.E.) portal clearance value of R- and S-carvedilol in control rats was 72 ± 16 and 156 ± 31 ml/min/kg, respectively, whereas that of the R- and S-enantiomers in hypoxic rats was 68 ± 8 and 113 ± 14 ml/min/kg, respectively.",Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739952/),[ml] / [kg·min],72,144652,DB02701,Nicotinamide
,23739952,portal clearance,"The mean (±S.E.) portal clearance value of R- and S-carvedilol in control rats was 72 ± 16 and 156 ± 31 ml/min/kg, respectively, whereas that of the R- and S-enantiomers in hypoxic rats was 68 ± 8 and 113 ± 14 ml/min/kg, respectively.",Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739952/),[ml] / [kg·min],156,144653,DB02701,Nicotinamide
,23739952,portal clearance,"The mean (±S.E.) portal clearance value of R- and S-carvedilol in control rats was 72 ± 16 and 156 ± 31 ml/min/kg, respectively, whereas that of the R- and S-enantiomers in hypoxic rats was 68 ± 8 and 113 ± 14 ml/min/kg, respectively.",Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739952/),[ml] / [kg·min],68,144654,DB02701,Nicotinamide
,23739952,portal clearance,"The mean (±S.E.) portal clearance value of R- and S-carvedilol in control rats was 72 ± 16 and 156 ± 31 ml/min/kg, respectively, whereas that of the R- and S-enantiomers in hypoxic rats was 68 ± 8 and 113 ± 14 ml/min/kg, respectively.",Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739952/),[ml] / [kg·min],113,144655,DB02701,Nicotinamide
,21246251,response rate,"Five patients had confirmed partial response and 11 had stable disease, a response rate of 27.8%.",Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21246251/),%,27.8,146507,DB02701,Nicotinamide
,10883413,peak concentrations,"In subjects receiving IVIG-L, peak concentrations of the stabilizer nicotinamide ranged from 0.34 to 0.47 mmol/L and of nicotinamide-N-oxide from 0.03 to 0.04 mmol/L, which are below those reported to cause adverse events.","Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883413/),[mM] / [l],0.34 to 0.47,148982,DB02701,Nicotinamide
,10883413,peak concentrations,"In subjects receiving IVIG-L, peak concentrations of the stabilizer nicotinamide ranged from 0.34 to 0.47 mmol/L and of nicotinamide-N-oxide from 0.03 to 0.04 mmol/L, which are below those reported to cause adverse events.","Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883413/),[mM] / [l],0.03 to 0.04,148983,DB02701,Nicotinamide
,29425861,EC50,"5,7-DMF significantly inhibited Bcrp1-mediated sorafenib efflux in a concentration dependent manner in MDCK/Bcrp1 cells, with EC50 value of 8.78 μM.","Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29425861/),μM,8.78,150933,DB02701,Nicotinamide
,29425861,AUC,"With 5,7-DMF, the AUC of sorafenib in plasma was 47,400 ± 4790 ng·h/mL, which was significantly higher than 27,300 ± 2650 ng·h/mL in sorafenib alone group.","Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29425861/),[h·ng] / [ml],"47,400",150934,DB02701,Nicotinamide
higher,29425861,AUC,"With 5,7-DMF, the AUC of sorafenib in plasma was 47,400 ± 4790 ng·h/mL, which was significantly higher than 27,300 ± 2650 ng·h/mL in sorafenib alone group.","Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29425861/),[h·ng] / [ml],"27,300",150935,DB02701,Nicotinamide
,22307138,IC(50),Sorafenib exhibited mixed-mode inhibition of UGT1A1-mediated bilirubin glucuronidation (IC(50) = 18 μmol/L; K(i) = 11.7 μmol/L) in vitro.,Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307138/),[μM] / [l],18,152703,DB02701,Nicotinamide
,22307138,K(i),Sorafenib exhibited mixed-mode inhibition of UGT1A1-mediated bilirubin glucuronidation (IC(50) = 18 μmol/L; K(i) = 11.7 μmol/L) in vitro.,Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22307138/),[μM] / [l],11.7,152704,DB02701,Nicotinamide
,8866342,maximal concentration in the serum (Cmax,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),[μg] / [ml],0.618,154457,DB02701,Nicotinamide
,8866342,maximal concentration in the serum (Cmax,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),[μg] / [ml],0.408,154458,DB02701,Nicotinamide
,8866342,area under the concentration curve (AUC,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),[h·μg] / [ml],1.039,154459,DB02701,Nicotinamide
,8866342,area under the concentration curve (AUC,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),[h·μg] / [ml],0.758,154460,DB02701,Nicotinamide
,8866342,CL,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),,0.579,154461,DB02701,Nicotinamide
,8866342,CL,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),,0.815,154462,DB02701,Nicotinamide
,8866342,Vd,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),,0.506,154463,DB02701,Nicotinamide
,8866342,Vd,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),,0.981,154464,DB02701,Nicotinamide
,133325,urinary excretion,"Average urinary excretion of tryptophan in the patient from 0 to 6 and 6 to 12 hr was 2.69 and 2.58 mumol/kg, respectively; that in the control subjects was 0.82 and 0.34 mumol/kg, respectively.",A defect in tryptophan metabolism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[μM] / [kg],2.69,154767,DB02701,Nicotinamide
,133325,urinary excretion,"Average urinary excretion of tryptophan in the patient from 0 to 6 and 6 to 12 hr was 2.69 and 2.58 mumol/kg, respectively; that in the control subjects was 0.82 and 0.34 mumol/kg, respectively.",A defect in tryptophan metabolism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[μM] / [kg],2.58,154768,DB02701,Nicotinamide
,133325,urinary excretion,"Average urinary excretion of tryptophan in the patient from 0 to 6 and 6 to 12 hr was 2.69 and 2.58 mumol/kg, respectively; that in the control subjects was 0.82 and 0.34 mumol/kg, respectively.",A defect in tryptophan metabolism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[μM] / [kg],0.82,154769,DB02701,Nicotinamide
,133325,urinary excretion,"Average urinary excretion of tryptophan in the patient from 0 to 6 and 6 to 12 hr was 2.69 and 2.58 mumol/kg, respectively; that in the control subjects was 0.82 and 0.34 mumol/kg, respectively.",A defect in tryptophan metabolism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[μM] / [kg],0.34,154770,DB02701,Nicotinamide
,133325,renal clearance,"However, the average renal clearance of tryptophan during the first 6 hr of the loading tests in the patient was 0.757 ml plasma/1.73 m2 and that in the control subjects was 0.706 ml plasma/1.73 m2.",A defect in tryptophan metabolism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[ml·plasma] / [1.73·m2],0.757,154771,DB02701,Nicotinamide
,133325,renal clearance,"However, the average renal clearance of tryptophan during the first 6 hr of the loading tests in the patient was 0.757 ml plasma/1.73 m2 and that in the control subjects was 0.706 ml plasma/1.73 m2.",A defect in tryptophan metabolism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/133325/),[ml·plasma] / [1.73·m2],0.706,154772,DB02701,Nicotinamide
,19369827,steady-state plasma levels,GMX1777 at a dose of 75 mg/kg administered over a 24 h intravenous infusion produced GMX1778 steady-state plasma levels of approximately 1 microg/ml and caused nicotinamide adenine dinucleotide levels to decrease significantly in tumors.,Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369827/),[μg] / [ml],1,159405,DB02701,Nicotinamide
,25835078,uptake,"Sorafenib uptake within liver tumor and nontumorous liver tissue peaked at mean 3.53 and 0.75 μg/mL, respectively, immediately post-procedure (5:1 tumor to normal tissue drug uptake ratio), before decreasing with a 10-18 hour half-life.",Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835078/),[μg] / [ml],3.53,165605,DB02701,Nicotinamide
,25835078,uptake,"Sorafenib uptake within liver tumor and nontumorous liver tissue peaked at mean 3.53 and 0.75 μg/mL, respectively, immediately post-procedure (5:1 tumor to normal tissue drug uptake ratio), before decreasing with a 10-18 hour half-life.",Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835078/),[μg] / [ml],0.75,165606,DB02701,Nicotinamide
,25835078,half-life,"Sorafenib uptake within liver tumor and nontumorous liver tissue peaked at mean 3.53 and 0.75 μg/mL, respectively, immediately post-procedure (5:1 tumor to normal tissue drug uptake ratio), before decreasing with a 10-18 hour half-life.",Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835078/),h,10-18,165607,DB02701,Nicotinamide
,25835078,half-life,"Serum sorafenib levels peaked immediately after TACE at a mean value of 58.58 μg/mL before normalizing with a 5.2-hour half-life, suggesting early drug washout from liver into the systemic circulation.",Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25835078/),h,5.2,165608,DB02701,Nicotinamide
,24670146,free concentration,This corresponds to a free concentration of 4.50 × 10(-12 ) M (pK = 11.3).,"Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24670146/),M,4.50 × 10(-12,166003,DB02701,Nicotinamide
,24670146,pK,This corresponds to a free concentration of 4.50 × 10(-12 ) M (pK = 11.3).,"Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24670146/),,11.3,166004,DB02701,Nicotinamide
,27681866,overall survival,The median overall survival was 14.4 months.,"A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681866/),month,14.4,166513,DB02701,Nicotinamide
,27681866,MTD,The MTD of selumetinib was 75 mg daily when combined with sorafenib 400 mg twice a day in CP ≤7 HCC.,"A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681866/),mg,75,166514,DB02701,Nicotinamide
,32192179,m/z transition,"KD025 and GSK429286A (the internal standard) in rat plasma samples were analyzed by high-performance liquid chromatography-tandem mass spectrometry with m/z transition values of 453.10 → 366.10 and 433.00 → 178.00, respectively.","Determination of KD025 (SLx-2119), a Selective ROCK2 Inhibitor, in Rat Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and its Pharmacokinetic Application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192179/),,453.10,167509,DB02701,Nicotinamide
,32192179,m/z transition,"KD025 and GSK429286A (the internal standard) in rat plasma samples were analyzed by high-performance liquid chromatography-tandem mass spectrometry with m/z transition values of 453.10 → 366.10 and 433.00 → 178.00, respectively.","Determination of KD025 (SLx-2119), a Selective ROCK2 Inhibitor, in Rat Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and its Pharmacokinetic Application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192179/),,366.10,167510,DB02701,Nicotinamide
,32192179,m/z transition,"KD025 and GSK429286A (the internal standard) in rat plasma samples were analyzed by high-performance liquid chromatography-tandem mass spectrometry with m/z transition values of 453.10 → 366.10 and 433.00 → 178.00, respectively.","Determination of KD025 (SLx-2119), a Selective ROCK2 Inhibitor, in Rat Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and its Pharmacokinetic Application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192179/),,433.00,167511,DB02701,Nicotinamide
,32192179,m/z transition,"KD025 and GSK429286A (the internal standard) in rat plasma samples were analyzed by high-performance liquid chromatography-tandem mass spectrometry with m/z transition values of 453.10 → 366.10 and 433.00 → 178.00, respectively.","Determination of KD025 (SLx-2119), a Selective ROCK2 Inhibitor, in Rat Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and its Pharmacokinetic Application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192179/),,178.00,167512,DB02701,Nicotinamide
,22805325,prostatic serum antigen,The median age was 73 (57-89); median prostatic serum antigen was 284 ng ml(-1) (11.7-9027).,Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22805325/),[ng] / [ml],284,167818,DB02701,Nicotinamide
,22805325,time to progression,Median time to progression was 2 months (1-5).,Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22805325/),month,2,167819,DB02701,Nicotinamide
,20562093,t(max),"t(max) of NA were on average 0.75 h in dialysis patients and 3.0 h in CKD patients and, therefore, especially for dialysis patients, clearly shorter than expected for extended-release formulations.",Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20562093/),h,0.75,170185,DB02701,Nicotinamide
,20562093,t(max),"t(max) of NA were on average 0.75 h in dialysis patients and 3.0 h in CKD patients and, therefore, especially for dialysis patients, clearly shorter than expected for extended-release formulations.",Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20562093/),h,3.0,170186,DB02701,Nicotinamide
,21695438,PFS,"After a median follow-up duration of 8.6 months (range, 3.7-14.2 months), median PFS was 3.9 months (95% CI, 0.8-7.0 months) and median OS was 10.4 months (95% CI, 0-22.4 months).",Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695438/),month,3.9,171646,DB02701,Nicotinamide
,21695438,OS,"After a median follow-up duration of 8.6 months (range, 3.7-14.2 months), median PFS was 3.9 months (95% CI, 0.8-7.0 months) and median OS was 10.4 months (95% CI, 0-22.4 months).",Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695438/),month,10,171647,DB02701,Nicotinamide
,26207356,steady state concentration,The mean ± SD steady state concentration during cycle 1 day 15 was 6.5 ± 3.9 μg/ml (n = 10).,Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207356/),[μg] / [ml],6.5,172028,DB02701,Nicotinamide
,21367805,progression-free survival,Median progression-free survival was 6.3 months.,Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21367805/),month,6.3,174469,DB02701,Nicotinamide
,22615057,progression free survival (PFS),The median progression free survival (PFS) and overall survival (OS) were 2.5 and 4.7 months respectively.,"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615057/),month,2.5,175046,DB02701,Nicotinamide
,22615057,overall survival (OS),The median progression free survival (PFS) and overall survival (OS) were 2.5 and 4.7 months respectively.,"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615057/),month,4.7,175047,DB02701,Nicotinamide
,2140114,limit of,"Photoconductivity, performed with the Tracor 965 photoconductivity detector, provided a limit of detection of 2 ng/ml in plasma (between-day coefficient of variation of 15%) but the linear range of response was limited to only about 100 ng/ml.",Determination of nicorandil in plasma using high-performance liquid chromatography with photoconductivity and ultraviolet detection. Application to pre-clinical pharmacokinetics in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140114/),[ng] / [ml],2,179929,DB02701,Nicotinamide
,2140114,maximum concentration,"The oral solution was absorbed rapidly, achieving an average maximum concentration of 857 ng/ml in 11.2 min.",Determination of nicorandil in plasma using high-performance liquid chromatography with photoconductivity and ultraviolet detection. Application to pre-clinical pharmacokinetics in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140114/),[ng] / [ml],857,179930,DB02701,Nicotinamide
,2140114,absolute bioavailability,The absolute bioavailability of nicorandil in dogs in this study was determined to be 84.2%.,Determination of nicorandil in plasma using high-performance liquid chromatography with photoconductivity and ultraviolet detection. Application to pre-clinical pharmacokinetics in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140114/),%,84.2,179931,DB02701,Nicotinamide
,8070006,initial half-life,The initial half-life increased significantly (P < 0.05) from 0.8 to 2 h and the terminal half-life increased from 3.4 to 5.6 h over the dose range studied.,Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),h,0.8 to 2,181067,DB02701,Nicotinamide
,8070006,terminal half-life,The initial half-life increased significantly (P < 0.05) from 0.8 to 2 h and the terminal half-life increased from 3.4 to 5.6 h over the dose range studied.,Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),h,3.4 to 5.6,181068,DB02701,Nicotinamide
,8070006,Clearance,"Clearance, however, decreased significantly from 0.3 to 0.24 l kg-1 h-1 only at the highest dose.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[l] / [h·kg],0.3,181069,DB02701,Nicotinamide
,8070006,Clearance,"Clearance, however, decreased significantly from 0.3 to 0.24 l kg-1 h-1 only at the highest dose.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[l] / [h·kg],0.24,181070,DB02701,Nicotinamide
,8070006,Peak concentrations,"Peak concentrations increased in a dose-dependent manner from 1,000 to 4,800 nmol/ml.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[nM] / [ml],"1,",181071,DB02701,Nicotinamide
,8070006,peak concentration,"The main plasma metabolite in the mouse is nicotinamide N-oxide, the peak concentration of which increased only from 80 to 160 nmol/ml.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[nM] / [ml],80,181072,DB02701,Nicotinamide
,8070006,peak concentration,"The main plasma metabolite in the mouse is nicotinamide N-oxide, the peak concentration of which increased only from 80 to 160 nmol/ml.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[nM] / [ml],160,181073,DB02701,Nicotinamide
,8070006,peak concentrations,"The N-oxide, which is also a weak radiosensitizer, is subject to reduction to the parent nicotinamide following administration at a dose of 276 mg/kg; peak concentrations of the N-oxide of 1900 nmol/ml were reached in 10 min, whereas concentrations of nicotinamide produced by reduction reached a maximum of 144 nmol/ml at 1 h.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[nM] / [ml],1900,181074,DB02701,Nicotinamide
,8070006,peak concentrations,"The N-oxide, which is also a weak radiosensitizer, is subject to reduction to the parent nicotinamide following administration at a dose of 276 mg/kg; peak concentrations of the N-oxide of 1900 nmol/ml were reached in 10 min, whereas concentrations of nicotinamide produced by reduction reached a maximum of 144 nmol/ml at 1 h.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),nm,144,181075,DB02701,Nicotinamide
,8070006,initial,"Elimination of the N-oxide was also biphasic, with initial and terminal half-lives being 0.39 and 1.8 h, respectively.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),h,0.39,181076,DB02701,Nicotinamide
,8070006,terminal half-lives,"Elimination of the N-oxide was also biphasic, with initial and terminal half-lives being 0.39 and 1.8 h, respectively.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),h,1.8,181077,DB02701,Nicotinamide
,8070006,bioavailability,The bioavailability of both drugs given via the i.p. as compared with the i.v. route was close to 100%.,Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),%,100,181078,DB02701,Nicotinamide
,18508468,absorption rate,"In the gut sac, NADH had a concentration-independent absorption rate of about 5 percent and the in vivo laser-induced fluorescence spectroscopy revealed a relatively quick absorption of NADH starting after a few minute reaching a plateau (about 5 percent ) after 20-30 minutes.",Pharmacokinetic aspects of reduced nicotinamide adenine dinucleotide (NADH) in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18508468/),%,5,181677,DB02701,Nicotinamide
,31645371,PFS,"The five included patients had median PFS of 3.8 months (range, 1.7-10.8) and OS of 7.4 months (range, 1.7-25.8).",Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31645371/),month,3.8,185088,DB02701,Nicotinamide
,31645371,OS,"The five included patients had median PFS of 3.8 months (range, 1.7-10.8) and OS of 7.4 months (range, 1.7-25.8).",Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31645371/),month,7.4,185089,DB02701,Nicotinamide
,15911315,IC(50),We have discovered a novel NCX inhibitor (23 h) with an IC(50) value of 0.12 microM against reverse NCX.,Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15911315/),μM,0.12,185425,DB02701,Nicotinamide
,21350850,area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[h·mg] / [l],38.1,186875,DB02701,Nicotinamide
,21350850,maximum plasma concentration (C(max)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[mg] / [l],4.9,186876,DB02701,Nicotinamide
,8436151,half-life,Mean plasma nicorandil concentrations were dose-related and fell with a half-life of 0.7 to 1.2 h.,The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436151/),h,0.7 to 1.2,189578,DB02701,Nicotinamide
≥,24135988,maximal sorafenib concentration,"In addition, a trend of prolonged overall survival was observed in HCC patients who achieved a maximal sorafenib concentration of ≥4.78 μg/mL during treatment compared with those who did not achieve the threshold concentration (12.0 vs. 6.5 months; log-rank p = 0.0824).",Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135988/),[μg] / [ml],4.78,191268,DB02701,Nicotinamide
,24726286,progression-free survival,"The median progression-free survival and overall survival for 25 evaluable patients were 10.6 and 12.6 months, respectively.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,10.6,192008,DB02701,Nicotinamide
,24726286,overall survival,"The median progression-free survival and overall survival for 25 evaluable patients were 10.6 and 12.6 months, respectively.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,12.6,192009,DB02701,Nicotinamide
,24726286,overall survival,"The median overall survival for patients with VEGF-A -2578 AA, -1498 CC, and -1154 AA versus alternate genotypes was 21.6 versus 14.7 months.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,21.6,192010,DB02701,Nicotinamide
,24726286,overall survival,"The median overall survival for patients with VEGF-A -2578 AA, -1498 CC, and -1154 AA versus alternate genotypes was 21.6 versus 14.7 months.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,14.7,192011,DB02701,Nicotinamide
,21321086,PFS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,7.7,192365,DB02701,Nicotinamide
,21321086,PFS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,5.8,192366,DB02701,Nicotinamide
,21321086,PFS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,8,192367,DB02701,Nicotinamide
,21321086,OS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,14.0,192368,DB02701,Nicotinamide
,21321086,OS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,12.8,192369,DB02701,Nicotinamide
,9783883,peak plasma concentrations,"In the 48 complete sets of blood samples, peak plasma concentrations ranged from 787 to 2312 nmol/ml with a median value of 1166 nmol/ml.",Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783883/),[nM] / [ml],787 to 2312,193463,DB02701,Nicotinamide
,9783883,peak plasma concentrations,"In the 48 complete sets of blood samples, peak plasma concentrations ranged from 787 to 2312 nmol/ml with a median value of 1166 nmol/ml.",Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783883/),[nM] / [ml],1166,193464,DB02701,Nicotinamide
,9783883,t1/2,"The median t1/2 for all 15 cases was 9.3 h, with minimum and maximum values of 4.2 and 26.8 h.",Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783883/),h,9.3,193465,DB02701,Nicotinamide
,9783883,t1/2,"The median t1/2 for all 15 cases was 9.3 h, with minimum and maximum values of 4.2 and 26.8 h.",Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783883/),h,4.2,193466,DB02701,Nicotinamide
,9783883,t1/2,"The median t1/2 for all 15 cases was 9.3 h, with minimum and maximum values of 4.2 and 26.8 h.",Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783883/),h,26.8,193467,DB02701,Nicotinamide
,12959253,t 1/2,"We found that tryptamide undergoes fast absorption (t 1/2 = 4.92-17.5 min) and elimination (t 1/2 = 55.72-74.52 min), can reach C(max) values (11-13 microg/cm3) after 30 min, and gives AUC values in the range of 21.40-27.30 (microg x h/cm3).",Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959253/),min,4.92-17.5,202013,DB02701,Nicotinamide
,12959253,t 1/2,"We found that tryptamide undergoes fast absorption (t 1/2 = 4.92-17.5 min) and elimination (t 1/2 = 55.72-74.52 min), can reach C(max) values (11-13 microg/cm3) after 30 min, and gives AUC values in the range of 21.40-27.30 (microg x h/cm3).",Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959253/),min,55.72-74.52,202014,DB02701,Nicotinamide
,12959253,C(max),"We found that tryptamide undergoes fast absorption (t 1/2 = 4.92-17.5 min) and elimination (t 1/2 = 55.72-74.52 min), can reach C(max) values (11-13 microg/cm3) after 30 min, and gives AUC values in the range of 21.40-27.30 (microg x h/cm3).",Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959253/),[μg] / [cm3],11-13,202015,DB02701,Nicotinamide
,12959253,AUC,"We found that tryptamide undergoes fast absorption (t 1/2 = 4.92-17.5 min) and elimination (t 1/2 = 55.72-74.52 min), can reach C(max) values (11-13 microg/cm3) after 30 min, and gives AUC values in the range of 21.40-27.30 (microg x h/cm3).",Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959253/),[h·μg] / [cm3],21.40-27.30,202016,DB02701,Nicotinamide
,17725178,Cmax,Mean niacin Cmax and AUC(0-t) values were 9.3 microg/ml and 26.2 microg x h/ml and were the highest of all analytes measured.,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),[μg] / [ml],9.3,204715,DB02701,Nicotinamide
,17725178,AUC(0-t),Mean niacin Cmax and AUC(0-t) values were 9.3 microg/ml and 26.2 microg x h/ml and were the highest of all analytes measured.,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),[h·μg] / [ml],26.2,204716,DB02701,Nicotinamide
,17725178,tmax,"Peak niacin and NUA levels occurred at 4.6 h (median) while tmax for NAM and NNO were 8.6 and 11.1 h, respectively.",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,8.6,204717,DB02701,Nicotinamide
,17725178,tmax,"Peak niacin and NUA levels occurred at 4.6 h (median) while tmax for NAM and NNO were 8.6 and 11.1 h, respectively.",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,11.1,204718,DB02701,Nicotinamide
,17725178,plasma terminal half-life,The mean plasma terminal half-life for niacin (0.9 h) and NUA (1.3 h) was shorter as compared to NAM (4.3 h).,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,0.9,204719,DB02701,Nicotinamide
,17725178,plasma terminal half-life,The mean plasma terminal half-life for niacin (0.9 h) and NUA (1.3 h) was shorter as compared to NAM (4.3 h).,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,1.3,204720,DB02701,Nicotinamide
,17725178,plasma terminal half-life,The mean plasma terminal half-life for niacin (0.9 h) and NUA (1.3 h) was shorter as compared to NAM (4.3 h).,Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,4.3,204721,DB02701,Nicotinamide
,17725178,recovery,"The highest recovery was for 2PY (37.9%), followed by MNA (16.0%) and NUA (11.6%).",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),%,37.9,204722,DB02701,Nicotinamide
,17725178,recovery,"The highest recovery was for 2PY (37.9%), followed by MNA (16.0%) and NUA (11.6%).",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),%,16.0,204723,DB02701,Nicotinamide
,17725178,recovery,"The highest recovery was for 2PY (37.9%), followed by MNA (16.0%) and NUA (11.6%).",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),%,11.6,204724,DB02701,Nicotinamide
,17725178,half-lives,"Mean half-lives for 2PY and MNA calculated in urine were 12.6 and 12.8 h, respectively.",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,12.6,204725,DB02701,Nicotinamide
,17725178,half-lives,"Mean half-lives for 2PY and MNA calculated in urine were 12.6 and 12.8 h, respectively.",Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725178/),h,12.8,204726,DB02701,Nicotinamide
,20706860,plasma concentration,"On day 45, sorafenib plasma concentration was stable (10.8 mg/L) before declining on days 60 and 75 (7.0 mg/L and 7.4 mg/L, respectively), which was probably related to an occurrence of grade-2 diarrhea.",Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20706860/),[mg] / [l],7.0,206263,DB02701,Nicotinamide
,20706860,plasma concentration,"On day 45, sorafenib plasma concentration was stable (10.8 mg/L) before declining on days 60 and 75 (7.0 mg/L and 7.4 mg/L, respectively), which was probably related to an occurrence of grade-2 diarrhea.",Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20706860/),mg,7.4,206264,DB02701,Nicotinamide
,30660839,Flow rate,Flow rate of 0. 45 mL/min with a run time of 5 min was used for separation.,Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30660839/),[ml] / [min],0. 45,207053,DB02701,Nicotinamide
,30660839,run time,Flow rate of 0. 45 mL/min with a run time of 5 min was used for separation.,Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30660839/),min,5,207054,DB02701,Nicotinamide
,30665192,flow rate,"Chromatographic separation was performed on Acquity™ UPLC BEH™ C18 column (100 mm × 2.1 mm i.d., 1.7 μm; Waters Corp., USA) using a mobile phase comprising of 0.1% formic acid acetonitrile: ammonium acetate (90:10 v/v) eluted at a flow rate of 0.25 mL/min.",Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30665192/),[ml] / [min],0.25,207071,DB02701,Nicotinamide
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,27.2,209604,DB02701,Nicotinamide
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,6.3,209605,DB02701,Nicotinamide
,25552403,K i,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,28.9,209606,DB02701,Nicotinamide
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,133.9,209607,DB02701,Nicotinamide
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,29.1,209608,DB02701,Nicotinamide
,25552403,IC50,"Trimethoprim inhibited metformin transport with K i values of 27.2, 6.3, and 28.9 μM and NMN transport with IC50 values of 133.9, 29.1, and 0.61 μM for OCT2, MATE1, and MATE2-K, respectively.",N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25552403/),μM,0.61,209609,DB02701,Nicotinamide
,28194539,MTD,"Nine patients had dose-limiting toxicities (stomatitis, thrombocytopenia, serum creatinine phosphokinase increase, visual impairment) and the MTD was determined as 45 mg/day pimasertib plus 25 mg/week temsirolimus.",Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28194539/),mg,45,209857,DB02701,Nicotinamide
,12440156,Disintegration time,"Disintegration time of the prepared FD tablets was sufficiently fast (i.e., 12 to 23 s).",[Fast-disintegration oral tablets having sustained release property]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12440156/),s,12 to 23,211662,DB02701,Nicotinamide
,23299770,overall survival,"Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months.","CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23299770/),month,7.8,212192,DB02701,Nicotinamide
,23299770,overall survival,"Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months.","CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23299770/),%,28,212193,DB02701,Nicotinamide
,23299770,overall survival,"Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months.","CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23299770/),month,8.1,212194,DB02701,Nicotinamide
,32761799,peak concentrations,"Apocynin peak concentrations were detected in plasma at 1 minute (5494 ± 400 ng/mL) (t1/2 = 0.05 hours, clearance = 7.76 L/h/kg), in urine at 15 minutes (14 942 ± 5977 ng/mL), in liver at 5 minutes (2853 ± 35 ng/g), in heart at 5 minutes (3161 ± 309 ng/g) and in brain at 1 minute (4603 ± 208 ng/g) after iv injection.",In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32761799/),[ng] / [ml],5494,215644,DB02701,Nicotinamide
,32761799,t1/2,"Apocynin peak concentrations were detected in plasma at 1 minute (5494 ± 400 ng/mL) (t1/2 = 0.05 hours, clearance = 7.76 L/h/kg), in urine at 15 minutes (14 942 ± 5977 ng/mL), in liver at 5 minutes (2853 ± 35 ng/g), in heart at 5 minutes (3161 ± 309 ng/g) and in brain at 1 minute (4603 ± 208 ng/g) after iv injection.",In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32761799/),h,0.05,215645,DB02701,Nicotinamide
,32761799,clearance,"Apocynin peak concentrations were detected in plasma at 1 minute (5494 ± 400 ng/mL) (t1/2 = 0.05 hours, clearance = 7.76 L/h/kg), in urine at 15 minutes (14 942 ± 5977 ng/mL), in liver at 5 minutes (2853 ± 35 ng/g), in heart at 5 minutes (3161 ± 309 ng/g) and in brain at 1 minute (4603 ± 208 ng/g) after iv injection.",In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32761799/),[l] / [h·kg],7.76,215646,DB02701,Nicotinamide
,32761799,clearance,"Apocynin peak concentrations were detected in plasma at 1 minute (5494 ± 400 ng/mL) (t1/2 = 0.05 hours, clearance = 7.76 L/h/kg), in urine at 15 minutes (14 942 ± 5977 ng/mL), in liver at 5 minutes (2853 ± 35 ng/g), in heart at 5 minutes (3161 ± 309 ng/g) and in brain at 1 minute (4603 ± 208 ng/g) after iv injection.",In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32761799/),[ng] / [ml],14 942,215647,DB02701,Nicotinamide
,32761799,clearance,"Apocynin peak concentrations were detected in plasma at 1 minute (5494 ± 400 ng/mL) (t1/2 = 0.05 hours, clearance = 7.76 L/h/kg), in urine at 15 minutes (14 942 ± 5977 ng/mL), in liver at 5 minutes (2853 ± 35 ng/g), in heart at 5 minutes (3161 ± 309 ng/g) and in brain at 1 minute (4603 ± 208 ng/g) after iv injection.",In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32761799/),[ng] / [g],2853,215648,DB02701,Nicotinamide
,32761799,clearance,"Apocynin peak concentrations were detected in plasma at 1 minute (5494 ± 400 ng/mL) (t1/2 = 0.05 hours, clearance = 7.76 L/h/kg), in urine at 15 minutes (14 942 ± 5977 ng/mL), in liver at 5 minutes (2853 ± 35 ng/g), in heart at 5 minutes (3161 ± 309 ng/g) and in brain at 1 minute (4603 ± 208 ng/g) after iv injection.",In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32761799/),[ng] / [g],3161,215649,DB02701,Nicotinamide
,32761799,clearance,"Apocynin peak concentrations were detected in plasma at 1 minute (5494 ± 400 ng/mL) (t1/2 = 0.05 hours, clearance = 7.76 L/h/kg), in urine at 15 minutes (14 942 ± 5977 ng/mL), in liver at 5 minutes (2853 ± 35 ng/g), in heart at 5 minutes (3161 ± 309 ng/g) and in brain at 1 minute (4603 ± 208 ng/g) after iv injection.",In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32761799/),[ng] / [g],4603,215650,DB02701,Nicotinamide
,28404979,steady state plasma concentration,"The steady state plasma concentration of sorafenib after 2 weeks of treatment ranged from 881 to 12,526 ng/mL.",In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),[ng] / [ml],"881 to 12,526",218581,DB02701,Nicotinamide
,28404979,Objective response,Objective response and disease control rates were 17.02% and 69.14%.,In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),%,17.02,218582,DB02701,Nicotinamide
,28404979,disease control rates,Objective response and disease control rates were 17.02% and 69.14%.,In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),%,69.14,218583,DB02701,Nicotinamide
>,28404979,Plasma concentration,"Plasma concentration of sorafenib was >10,000 ng/mL in patients with severe ADRs, which decreased with reduction in dose or discontinuation of treatment.",In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),[ng] / [ml],"10,000",218584,DB02701,Nicotinamide
,28404979,progression free survival,"After 21.2 weeks follow-up, median progression free survival was 12.3 months.",In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404979/),month,12.3,218585,DB02701,Nicotinamide
,25294897,Disease control rate,Disease control rate was 44.8% (primary efficacy analysis; n = 58).,A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294897/),%,44.8,220446,DB02701,Nicotinamide
,25294897,time to progression,"Median time to progression was 122 days, median overall survival was 290 days (n = 70).",A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294897/),d,122,220447,DB02701,Nicotinamide
,25294897,overall survival,"Median time to progression was 122 days, median overall survival was 290 days (n = 70).",A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294897/),d,290,220448,DB02701,Nicotinamide
,7607932,absolute peak concentrations,Large interpatient variations in absolute peak concentrations were seen from 0.4 to 1.4 mumol/ml (mean 0.9 +/- 0.3; standard deviation (SD)).,"Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7607932/),[μM] / [ml],0.9,222488,DB02701,Nicotinamide
,7607932,time taken to peak concentration,The time taken to peak concentration was also very variable from 0.8 to 4 h (mean 2.1 +/- 1.3 h; SD).,"Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7607932/),h,2.1,222489,DB02701,Nicotinamide
>,7607932,absolute plasma levels,"In 70% of the samples, absolute plasma levels > or = 0.7 mumol/ml were reached within 1-2 h after administration and maintained for up to 6 h (mean 2.8 +/- 1.8 h; SD).","Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7607932/),[μM] / [ml],0.7,222490,DB02701,Nicotinamide
,7607932,half-life,"There was a small but nonsignificant increase in the half-life of nicotinamide when the dose was increased from 80 to 90 or 100 mg/kg (7.1 h and 8.6 h, respectively).","Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7607932/),h,7.1,222491,DB02701,Nicotinamide
,7607932,half-life,"There was a small but nonsignificant increase in the half-life of nicotinamide when the dose was increased from 80 to 90 or 100 mg/kg (7.1 h and 8.6 h, respectively).","Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7607932/),h,8.6,222492,DB02701,Nicotinamide
,21791058,MTD,The MTD of motesanib in combination with gemcitabine and erlotinib was 100 mg QD.,Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21791058/),mg,100,229474,DB02701,Nicotinamide
,20927524,limit of detection,The limit of detection is 0.25 ng/ml.,High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20927524/),[ng] / [ml],0.25,231642,DB02701,Nicotinamide
above,20927524,recovery,Sorafenib recovery in spiked probes of peritoneal fluid was above 85%.,High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20927524/),%,85,231643,DB02701,Nicotinamide
,15993975,flux,The flux of nicorandil from the nerodilol-based HMPC drug reservoir across excised rat skin (control) was 384.0+/-4.6 microg/cm2 h and this decreased to 222.7+/-7.1 microg/cm2 h when studied across EVA2825 membrane indicating that EVA2825 membrane was effective as rate controlling membrane.,Bioavailability of nerodilol-based transdermal therapeutic system of nicorandil in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993975/),[μg] / [cm2·h],384.0,234781,DB02701,Nicotinamide
,15993975,flux,The flux of nicorandil from the nerodilol-based HMPC drug reservoir across excised rat skin (control) was 384.0+/-4.6 microg/cm2 h and this decreased to 222.7+/-7.1 microg/cm2 h when studied across EVA2825 membrane indicating that EVA2825 membrane was effective as rate controlling membrane.,Bioavailability of nerodilol-based transdermal therapeutic system of nicorandil in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993975/),[μg] / [cm2·h],222.7,234782,DB02701,Nicotinamide
,15993975,flux,The flux of the drug decreased to 183.8+/-5.7 microg/cm2 h on application of a water-based acrylic adhesive (TACKWHITE A 4MED) coat to EVA2825 membrane.,Bioavailability of nerodilol-based transdermal therapeutic system of nicorandil in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993975/),[μg] / [cm2·h],183.8,234783,DB02701,Nicotinamide
,15993975,flux,"However, the flux of nicorandil across adhesive-coated EVA2825-membrane-rat-skin composite was 164.8+/-1.8 microg/cm2 h, which was 1.74-times of the required flux that prompted for preparation of TTS.",Bioavailability of nerodilol-based transdermal therapeutic system of nicorandil in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993975/),[μg] / [cm2·h],164.8,234784,DB02701,Nicotinamide
,15993975,steady-state plasma concentration,The nerodilol-based TTS provided a steady-state plasma concentration of 25.5 ng/ml for 24 h in human volunteers.,Bioavailability of nerodilol-based transdermal therapeutic system of nicorandil in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993975/),[ng] / [ml],25.5,234785,DB02701,Nicotinamide
,2525322,Absolute bioavailability,Absolute bioavailability is 75 +/- 23% (mean +/- standard deviation) indicating that no significant hepatic first-pass effect exists; peak plasma levels occur within 0.30 to 1.0 hours after dosing.,Pharmacokinetics of nicorandil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525322/),%,75,235657,DB02701,Nicotinamide
,2525322,apparent distribution volume,"The apparent distribution volume is about 1.4 liters/kg and the plasma concentrations decline according to 2 different processes: (1) a rapid elimination phase (apparent t1/2 beta congruent to 1 hour) that involves about 96% of the dose found in plasma, and a slower phase between the eighth and twenty-fourth hour that could be the consequence of the vascular affinity of the compound.",Pharmacokinetics of nicorandil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525322/),[l] / [kg],1.4,235658,DB02701,Nicotinamide
,2525322,apparent t1/2 beta,"The apparent distribution volume is about 1.4 liters/kg and the plasma concentrations decline according to 2 different processes: (1) a rapid elimination phase (apparent t1/2 beta congruent to 1 hour) that involves about 96% of the dose found in plasma, and a slower phase between the eighth and twenty-fourth hour that could be the consequence of the vascular affinity of the compound.",Pharmacokinetics of nicorandil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525322/),h,1,235659,DB02701,Nicotinamide
greater,2525322,free fraction,Nicorandil is weakly bound to human plasma proteins (free fraction greater than 75%) and its mean residence time is close to 1.25 hour.,Pharmacokinetics of nicorandil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525322/),%,75,235660,DB02701,Nicotinamide
,2525322,mean residence time,Nicorandil is weakly bound to human plasma proteins (free fraction greater than 75%) and its mean residence time is close to 1.25 hour.,Pharmacokinetics of nicorandil. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525322/),h,1.25,235661,DB02701,Nicotinamide
,27592284,flow rate,"The separation of both the analytes and internal standard was achieved on Discovery HS C18 column (250mm×4.6mm, 5μm) using Acetonitrile and TFA (0.025%) in the ratio of (65:35V/V) as the mobile phase in isocratic mode at a flow rate of 1ml/min, with a wavelength of 245nm and at a column oven temperature of 25°Cin a short run time of 12min.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ml] / [min],1,237803,DB02701,Nicotinamide
,27592284,limits of,"The limits of detection (LLOD) were 5 and 10ng/ml while the limits of quantification (LLOQ) were 10 and 15ng/ml for sorafenib and paclitaxel, respectively.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ng] / [ml],5,237804,DB02701,Nicotinamide
,27592284,limits of,"The limits of detection (LLOD) were 5 and 10ng/ml while the limits of quantification (LLOQ) were 10 and 15ng/ml for sorafenib and paclitaxel, respectively.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ng] / [ml],10,237805,DB02701,Nicotinamide
,34060723,AUC0->12 h,Sorafenib steady-state exposures (area under the concentration curve from 0 to 12-h [AUC0->12 h ]) were simulated using published sorafenib pharmacokinetics at either a fixed dosage (90 mg/m2 /dose) or a pharmacokinetically guided dose targeting an AUC0->12 h between 20 and 55 h µg/ml.,Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34060723/),[h·μg] / [ml],20 and 55,238009,DB02701,Nicotinamide
,22787390,polydispersity index,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),mv,0.25,241906,DB02701,Nicotinamide
,22787390,zeta potential,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),mv,-,241907,DB02701,Nicotinamide
,22787390,zeta potential,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),mv,16.37,241908,DB02701,Nicotinamide
,22787390,EE,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),mv,16.37,241909,DB02701,Nicotinamide
,22787390,EE,"The polydispersity index, zeta potential, and EE were determined to be 0.25 ± 0.02, -16.37 ± 0.65 mV, and 93.49% ± 1.87%, respectively (n = 3).","Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22787390/),%,93.49,241910,DB02701,Nicotinamide
,22006162,AUC,"AUC increased less than proportionally with increasing doses [47.3 (41.3-63.3), 60.3 (56.3-64.4), 71.4 (51.3-99.1), 75.9 (45.5-100.9) mg/L.h for 400, 800, 1,200 and 1,600 mg/day, respectively].",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],47.3,243433,DB02701,Nicotinamide
,22006162,AUC,"AUC increased less than proportionally with increasing doses [47.3 (41.3-63.3), 60.3 (56.3-64.4), 71.4 (51.3-99.1), 75.9 (45.5-100.9) mg/L.h for 400, 800, 1,200 and 1,600 mg/day, respectively].",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],60.3,243434,DB02701,Nicotinamide
,22006162,AUC,"AUC increased less than proportionally with increasing doses [47.3 (41.3-63.3), 60.3 (56.3-64.4), 71.4 (51.3-99.1), 75.9 (45.5-100.9) mg/L.h for 400, 800, 1,200 and 1,600 mg/day, respectively].",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],71.4,243435,DB02701,Nicotinamide
,22006162,AUC,"AUC increased less than proportionally with increasing doses [47.3 (41.3-63.3), 60.3 (56.3-64.4), 71.4 (51.3-99.1), 75.9 (45.5-100.9) mg/L.h for 400, 800, 1,200 and 1,600 mg/day, respectively].",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],75.9,243436,DB02701,Nicotinamide
,22006162,AUC,"According to the simulations, dividing the daily dose in three or four doses for daily dose >800 mg would significantly increase AUC compared with a twice daily dosing regimen (101.7 vs 81.6 mg/L.h for 400 mg q8h and 600 mg q12h respectively; 131.6 vs 91.5 mg/L.h for 400 mg q6h and 800 mg q12h, respectively).",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],101.7,243437,DB02701,Nicotinamide
,22006162,AUC,"According to the simulations, dividing the daily dose in three or four doses for daily dose >800 mg would significantly increase AUC compared with a twice daily dosing regimen (101.7 vs 81.6 mg/L.h for 400 mg q8h and 600 mg q12h respectively; 131.6 vs 91.5 mg/L.h for 400 mg q6h and 800 mg q12h, respectively).",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],81.6,243438,DB02701,Nicotinamide
,22006162,AUC,"According to the simulations, dividing the daily dose in three or four doses for daily dose >800 mg would significantly increase AUC compared with a twice daily dosing regimen (101.7 vs 81.6 mg/L.h for 400 mg q8h and 600 mg q12h respectively; 131.6 vs 91.5 mg/L.h for 400 mg q6h and 800 mg q12h, respectively).",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],131.6,243439,DB02701,Nicotinamide
,22006162,AUC,"According to the simulations, dividing the daily dose in three or four doses for daily dose >800 mg would significantly increase AUC compared with a twice daily dosing regimen (101.7 vs 81.6 mg/L.h for 400 mg q8h and 600 mg q12h respectively; 131.6 vs 91.5 mg/L.h for 400 mg q6h and 800 mg q12h, respectively).",Saturable absorption of sorafenib in patients with solid tumors: a population model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006162/),[mg] / [h·l],91.5,243440,DB02701,Nicotinamide
,20395213,nonprogression rate,The nonprogression rate at 6 weeks was 74%: 12 (24%) partial response and 25 (50%) stable disease.,A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395213/),%,74,244829,DB02701,Nicotinamide
,20395213,time to progression,"Median time to progression was 5.0 months [95% confidence interval (95% CI), 3.2-6.8 months].",A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395213/),month,5.0,244830,DB02701,Nicotinamide
,20395213,overall survival,"Median overall survival was 10.9 months (95% CI, 3.8-18.1 months).",A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395213/),month,10.9,244831,DB02701,Nicotinamide
,15360088,tumour enhancement ratios,An almost eightfold increase in plasma levels increased tumour enhancement ratios from 1.74 to 1.92 (p < 0.0001).,Is sensitization with nicotinamide and carbogen dependent on nicotinamide concentration at the time of irradiation? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15360088/),,1.74,245456,DB02701,Nicotinamide
,15360088,tumour enhancement ratios,An almost eightfold increase in plasma levels increased tumour enhancement ratios from 1.74 to 1.92 (p < 0.0001).,Is sensitization with nicotinamide and carbogen dependent on nicotinamide concentration at the time of irradiation? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15360088/),,1.92,245457,DB02701,Nicotinamide
,31295152,time-to-tumor progression,"For the 150 mg b.i.d. galunisertib cohort, the median time-to-tumor progression was 4.1 months; the median OS was 18.8 months.",A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295152/),month,4.1,247113,DB02701,Nicotinamide
,31295152,OS,"For the 150 mg b.i.d. galunisertib cohort, the median time-to-tumor progression was 4.1 months; the median OS was 18.8 months.",A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295152/),month,18.8,247114,DB02701,Nicotinamide
,1535591,CL,"After the last dose CL was 51 l.h-1 in Group I, 44 l.h-1 in Group II and 56 l.h-1 in Group III, and it was not related to creatinine clearance.",Pharmacokinetics of nicorandil in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535591/),[l] / [h],51,249143,DB02701,Nicotinamide
,1535591,CL,"After the last dose CL was 51 l.h-1 in Group I, 44 l.h-1 in Group II and 56 l.h-1 in Group III, and it was not related to creatinine clearance.",Pharmacokinetics of nicorandil in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535591/),[l] / [h],44,249144,DB02701,Nicotinamide
,1535591,CL,"After the last dose CL was 51 l.h-1 in Group I, 44 l.h-1 in Group II and 56 l.h-1 in Group III, and it was not related to creatinine clearance.",Pharmacokinetics of nicorandil in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535591/),[l] / [h],56,249145,DB02701,Nicotinamide
,22542699,absolute,"Oral administration of antide in solution led to only very small detectable quantities in plasma with an absolute and relative bioavailability (BA) of 0.003 and 0.03%, only.",In vivo evaluation of an oral drug delivery system for peptides based on S-protected thiolated chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22542699/),%,0.003,249998,DB02701,Nicotinamide
,22542699,relative bioavailability (BA),"Oral administration of antide in solution led to only very small detectable quantities in plasma with an absolute and relative bioavailability (BA) of 0.003 and 0.03%, only.",In vivo evaluation of an oral drug delivery system for peptides based on S-protected thiolated chitosan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22542699/),%,0.03,249999,DB02701,Nicotinamide
,15870716,MTD,A MTD of 400 mg b.i.d. BAY 43-9006 was defined.,"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15870716/),mg,400,250113,DB02701,Nicotinamide
,20028752,MTD,The MTD was 125 mg once daily.,"Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20028752/),mg,125,252138,DB02701,Nicotinamide
,20028752,objective response rates,"The objective response rates were 17%, 0%, and 17% in arms A, B, and C, respectively.","Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20028752/),%,17,252139,DB02701,Nicotinamide
,20028752,objective response rates,"The objective response rates were 17%, 0%, and 17% in arms A, B, and C, respectively.","Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20028752/),%,0,252140,DB02701,Nicotinamide
,27405013,GI50,"In particular, it showed GI50 values of 51.4 and 19 nm against leukemia K-562 and colon carcinoma KM12 cell lines, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,51.4,252750,DB02701,Nicotinamide
,27405013,GI50,"In particular, it showed GI50 values of 51.4 and 19 nm against leukemia K-562 and colon carcinoma KM12 cell lines, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,19,252751,DB02701,Nicotinamide
,27405013,IC50,"Interestingly, 6 displays IC50 values of 0.82, 3.81, and 53 nm toward Tie2, TrkA, and ABL-1 (wild-type and T315I mutant) kinases, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,0.82,252752,DB02701,Nicotinamide
,27405013,IC50,"Interestingly, 6 displays IC50 values of 0.82, 3.81, and 53 nm toward Tie2, TrkA, and ABL-1 (wild-type and T315I mutant) kinases, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,3.81,252753,DB02701,Nicotinamide
,27405013,IC50,"Interestingly, 6 displays IC50 values of 0.82, 3.81, and 53 nm toward Tie2, TrkA, and ABL-1 (wild-type and T315I mutant) kinases, respectively.",Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405013/),nm,53,252754,DB02701,Nicotinamide
,32847973,Response rates,Response rates were 48% overall (27) and 64% for ovarian cancers (14).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),%,48,252812,DB02701,Nicotinamide
,32847973,Response rates,Response rates were 48% overall (27) and 64% for ovarian cancers (14).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),%,64,252813,DB02701,Nicotinamide
,32847973,overall,VEGF-A-1154AA and -7TT recessive homozygous genotypes conferred worse overall survival versus alternative genotypes (7 vs. 22 months).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),month,7,252814,DB02701,Nicotinamide
,32847973,overall,VEGF-A-1154AA and -7TT recessive homozygous genotypes conferred worse overall survival versus alternative genotypes (7 vs. 22 months).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),month,22,252815,DB02701,Nicotinamide
,27483391,total body clearance,"Following i.v. administration, [14 C]pimasertib exhibited a geometric mean total body clearance of 45.7 l h-1 (geometric coefficient of variation [geometric CV]: 47.2%) and a volume of distribution of 229 l (geometric CV: 42.0%).","Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27483391/),[l] / [h],45.7,253380,DB02701,Nicotinamide
,27483391,volume of distribution,"Following i.v. administration, [14 C]pimasertib exhibited a geometric mean total body clearance of 45.7 l h-1 (geometric coefficient of variation [geometric CV]: 47.2%) and a volume of distribution of 229 l (geometric CV: 42.0%).","Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27483391/),l,229,253381,DB02701,Nicotinamide
,27483391,Absolute bioavailability,Absolute bioavailability was 73%.,"Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27483391/),%,73,253382,DB02701,Nicotinamide
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,20,257868,DB02701,Nicotinamide
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,27,257869,DB02701,Nicotinamide
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,24,257870,DB02701,Nicotinamide
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),,27,257871,DB02701,Nicotinamide
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),%,14,257872,DB02701,Nicotinamide
,25772756,objective response rate,"The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %).",Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25772756/),,0,257873,DB02701,Nicotinamide
,21072558,Peak plasma concentrations,Peak plasma concentrations after IV dosing ranged from 3.4 to 7.6 μg/mL.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[μg] / [ml],3.4 to 7.6,258145,DB02701,Nicotinamide
,21072558,area under the plasma concentration from 0 to 24 h,"The mean ± standard deviation (SD) area under the plasma concentration from 0 to 24 h was 28 ± 4.3 μg • h/mL, which is comparable to the exposure observed in humans at recommended doses.",The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[h·μg] / [ml],28,258146,DB02701,Nicotinamide
,21072558,clearance,The mean ± SD clearance was 1.7 ± 0.5 mL/min/kg.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[ml] / [kg·min],1.7,258147,DB02701,Nicotinamide
,21072558,peak CSF concentrations,The peak CSF concentrations ranged from 0.00045 to 0.00058 μg/mL.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[μg] / [ml],0,258148,DB02701,Nicotinamide
,21072558,area under the CSF concentration from 0 to 24h,The mean ± SD area under the CSF concentration from 0 to 24h was 0.0048 ± 0.0016 μg•h/mL.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),[h·μg] / [ml],0.0048,258149,DB02701,Nicotinamide
,21072558,CSF penetration,The mean CSF penetration of sorafenib was 0.02% and 3.4% after correcting for plasma protein binding.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),%,0.02,258150,DB02701,Nicotinamide
,21072558,CSF penetration,The mean CSF penetration of sorafenib was 0.02% and 3.4% after correcting for plasma protein binding.,The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21072558/),%,3.4,258151,DB02701,Nicotinamide
,1282174,bioavailability,"Thus, it easily enters the systemic blood flow, resulting in almost complete bioavailability (75-100%).",Pharmacokinetic profile of nicorandil in humans: an overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),%,75-100,258555,DB02701,Nicotinamide
,1282174,Cmax,"On average, the Cmax then is approximately 300 ng/ml, which is achieved rapidly within 30 min after drug intake.",Pharmacokinetic profile of nicorandil in humans: an overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[ng] / [ml],300,258556,DB02701,Nicotinamide
,1282174,apparent volume of distribution,"After oral (and i.v.) administration of the drug, the apparent volume of distribution is approximately 1.0 L/kg body weight.",Pharmacokinetic profile of nicorandil in humans: an overview. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[l] / [body·kg·weight],1.0,258557,DB02701,Nicotinamide
,1282174,apparent elimination half-life,"The apparent elimination half-life is short (approximately 1 h), and total body clearance is close to 1.15 L/min, which is lower than the liver blood flow.",Pharmacokinetic profile of nicorandil in humans: an overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),h,1,258558,DB02701,Nicotinamide
,1282174,total body clearance,"The apparent elimination half-life is short (approximately 1 h), and total body clearance is close to 1.15 L/min, which is lower than the liver blood flow.",Pharmacokinetic profile of nicorandil in humans: an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[l] / [min],1.15,258559,DB02701,Nicotinamide
,23328813,overall survival,The median overall survival was 5.7 months.,NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328813/),month,5.7,261872,DB02701,Nicotinamide
,23328813,Progression-free survival,Progression-free survival at 6 months was 14%.,NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328813/),%,14,261873,DB02701,Nicotinamide
,28289865,Disease control rate,Disease control rate was ~29% with 1 partial response and 4 of 10 patients with stable disease >4 months.,"Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28289865/),%,29,262254,DB02701,Nicotinamide
,2869002,apparent volume of distribution,The drug was widely distributed with an apparent volume of distribution between 140 and 200 l.,"Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869002/),l,140 and 200,264365,DB02701,Nicotinamide
,2869002,plasma clearance,The plasma clearance was between 56 and 69 L/h.,"Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869002/),[l] / [h],56 and 69,264366,DB02701,Nicotinamide
,2869002,elimination half-life,The plasma concentrations declined following a monoexponential function with an elimination half-life of 2 h.,"Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869002/),h,2,264367,DB02701,Nicotinamide
less,29551745,polydispersity (PDI),"The developed SFN loaded PB-b-PEO polymersomes (SFN-PB-b-PEO, test formulation) characterized by DLS and cryo-TEM showed particle size 282 nm, polydispersity (PDI) of less than 0.29 and membrane thickness of about 20 nm.",Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551745/),,0.29,270363,DB02701,Nicotinamide
,8532910,maximum recorded plasma levels,Doses up to 6 g were well tolerated and resulted in average maximum recorded plasma levels (mean +/- 1 SEM) of 156.4 +/- 33.6 micrograms/ml.,Nicotinamide pharmacokinetics in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8532910/),[μg] / [ml],156.4,270412,DB02701,Nicotinamide
,22752067,12-hour,"For 83 patients (median age, 62 years; range, 21-84 years), median sorafenib 12-hour area under the curve (AUC(0-12)) was 52.8 mg · h/L (range: 11.8-199.6).",Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],52.8,272989,DB02701,Nicotinamide
,22752067,area under the curve (AUC(0-12)),"For 83 patients (median age, 62 years; range, 21-84 years), median sorafenib 12-hour area under the curve (AUC(0-12)) was 52.8 mg · h/L (range: 11.8-199.6).",Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],52.8,272990,DB02701,Nicotinamide
,22752067,AUC(0-12),Sorafenib AUC(0-12) preceding grade 3-4 toxicities was significantly higher than that observed in the remaining population (61.9 mg · h/L vs. 53 mg · h/L).,Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],61.9,272991,DB02701,Nicotinamide
,22752067,AUC(0-12),Sorafenib AUC(0-12) preceding grade 3-4 toxicities was significantly higher than that observed in the remaining population (61.9 mg · h/L vs. 53 mg · h/L).,Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],53,272992,DB02701,Nicotinamide
,22752067,dose-normalized AUC(0-12),"In 25 patients treated with fixed doses of sorafenib for the first 4 months, median dose-normalized AUC(0-12) on day 120 was significantly lower than on day 15 (63 vs. 102 mg · h/L).",Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],63,272993,DB02701,Nicotinamide
,22752067,dose-normalized AUC(0-12),"In 25 patients treated with fixed doses of sorafenib for the first 4 months, median dose-normalized AUC(0-12) on day 120 was significantly lower than on day 15 (63 vs. 102 mg · h/L).",Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752067/),[h·mg] / [l],102,272994,DB02701,Nicotinamide
,31967518,clearance,Patient's clearance (0.48 l/h) estimated by Bayesian approach was consistently lower than usually described.,Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31967518/),[l] / [h],0.48,273744,DB02701,Nicotinamide
,20872145,oral clearance,Motesanib oral clearance in patients with medullary thyroid cancer was 67% higher than in patients with differentiated thyroid cancer patients (73.7 vs. 44 L/h).,Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872145/),[l] / [h],73.7,274046,DB02701,Nicotinamide
,20872145,oral clearance,Motesanib oral clearance in patients with medullary thyroid cancer was 67% higher than in patients with differentiated thyroid cancer patients (73.7 vs. 44 L/h).,Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872145/),[l] / [h],44,274047,DB02701,Nicotinamide
,20872145,objective response rates,"The objective response rates were 14 versus 2% for differentiated thyroid cancer and medullary thyroid cancer, respectively.",Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872145/),%,14,274048,DB02701,Nicotinamide
,20872145,objective response rates,"The objective response rates were 14 versus 2% for differentiated thyroid cancer and medullary thyroid cancer, respectively.",Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872145/),%,2,274049,DB02701,Nicotinamide
